@NP	Undesired effects	1
@NP	a combinatorial treatment for spinal cord injury	22
@NP	a combinatorial treatment	22
@NP	spinal cord injury	52
@NP	transplantation of olfactory ensheathing cells	73
@NP	transplantation	73
@NP	olfactory ensheathing cells	92
@NP	BDNF infusion to the red nucleus	124
@NP	BDNF infusion	124
@NP	the red nucleus	141
@NP	Frederic Bretzner , Jie Liu , Erin Currie , A.	158
@NP	Frederic Bretzner	158
@NP	Jie Liu	177
@NP	Erin Currie	186
@NP	A.	199
@NP	Jane Roskams	202
@NP	Wolfram Tetzlaff ICORD	219
@NP	International Collaboration	243
@NP	Repair Discoveries	274
@NP	Departments	295
@NP	Zoology and Surgery	310
@NP	University of British Columbia , Vancouver , BC V6T 1Z4	331
@NP	University	331
@NP	British Columbia , Vancouver , BC V6T 1Z4	345
@NP	Canada Keywords	386
@NP	BDNF	403
@NP	cell body treatment	409
@NP	olfactory ensheathing cells	430
@NP	rat	459
@NP	regeneration	464
@NP	spinal cord injury Abstract Transplantations of olfactory ensheathing cells	478
@NP	spinal cord injury Abstract Transplantations	478
@NP	olfactory ensheathing cells	527
@NP	OECs	556
@NP	axonal regeneration and functional recovery	592
@NP	regeneration	599
@NP	spinal cord injury	642
@NP	limited growth promotion of rat rubrospinal axons	684
@NP	limited growth promotion	684
@NP	rat rubrospinal axons	712
@NP	a cervical dorsolateral funiculus crush	740
@NP	Rubrospinal neurons	781
@NP	massive atrophy	809
@NP	cervical axotomy	831
@NP	only transient expression of regenerationassociated genes	857
@NP	only transient expression	857
@NP	regenerationassociated genes	886
@NP	Cell body treatment with brain-derived neurotrophic factor -LRB- BDNF -RRB-	916
@NP	Cell body treatment with brain-derived neurotrophic factor	916
@NP	Cell body treatment	916
@NP	brain-derived neurotrophic factor	941
@NP	BDNF	976
@NP	this atrophy	991
@NP	regenerationassociated gene expression	1016
@NP	regeneration of rubrospinal axons	1068
@NP	regeneration	1068
@NP	rubrospinal axons	1084
@NP	peripheral nerve transplants	1107
@NP	we	1143
@NP	the failure	1164
@NP	rubrospinal axons	1179
@NP	a bridge of OEC transplants	1219
@NP	a bridge	1219
@NP	OEC transplants	1231
@NP	this weak intrinsic cell body response	1258
@NP	we	1305
@NP	BDNF treatment of rubrospinal neurons	1317
@NP	BDNF treatment	1317
@NP	rubrospinal neurons	1335
@NP	transplantation	1360
@NP	highly enriched OECs	1379
@NP	the nasal mucosa	1413
@NP	axonal regeneration as well as behavioral changes	1443
@NP	axonal regeneration	1443
@NP	behavioral changes	1474
@NP	a cervical dorsolateral funiculus crush	1499
@NP	Each treatment alone as well as their combination	1540
@NP	Each treatment alone	1540
@NP	Each treatment	1540
@NP	their combination	1572
@NP	the dieback of the rubrospinal axons	1600
@NP	the dieback	1600
@NP	the rubrospinal axons	1615
@NP	none of them	1642
@NP	none	1642
@NP	them	1650
@NP	rubrospinal regeneration	1664
@NP	the lesion ⁄ transplantation site	1696
@NP	Motor performance	1731
@NP	a food-pellet	1752
@NP	test and forelimb usage	1775
@NP	vertical exploration -LRB- cylinder test -RRB-	1806
@NP	vertical exploration	1806
@NP	cylinder test	1828
@NP	transplantation of OECs with BDNF treatment	1878
@NP	transplantation	1878
@NP	OECs with BDNF treatment	1897
@NP	OECs	1897
@NP	BDNF treatment	1907
@NP	This impaired motor performance	1923
@NP	lowered sensory thresholds	1971
@NP	animals	2001
@NP	the combinatorial therapy	2019
@NP	each treatment	2072
@NP	Only this combinatorial treatment group	2094
@NP	calcitonin gene-related peptide-positive axons rostral	2163
@NP	the lesion site	2221
@NP	some combinatorial treatments , such as OECs with BDNF ,	2245
@NP	some combinatorial treatments	2245
@NP	OECs with BDNF	2284
@NP	OECs	2284
@NP	BDNF	2294
@NP	undesired effects in the injured spinal cord	2309
@NP	undesired effects	2309
@NP	the injured spinal cord	2330
@NP	Introduction	2356
@NP	Olfactory ensheathing cells -LRB- OECs -RRB-	2369
@NP	Olfactory ensheathing cells	2369
@NP	OECs	2398
@NP	the olfactory bulb	2417
@NP	OB	2437
@NP	axonal regeneration , remyelination	2471
@NP	axonal regeneration	2471
@NP	remyelination	2492
@NP	functional recovery	2518
@NP	various types	2544
@NP	spinal cord injury	2561
@NP	Li	2581
@NP	et al. , 1997 ; Ramon-Cueto et al.	2584
@NP	et al. , 1997	2584
@NP	et al.	2584
@NP	1997	2592
@NP	Ramon-Cueto et al.	2598
@NP	Ramon-Cueto	2598
@NP	et al.	2610
@NP	1998 , 2000 ; Nash et al. , 2002 ; Keyvan-Fouladi et al. , 2003 ; Sasaki et al.	2618
@NP	1998 , 2000	2618
@NP	1998	2618
@NP	2000	2624
@NP	Nash et al. , 2002	2630
@NP	Nash	2630
@NP	et al. , 2002	2635
@NP	et al.	2635
@NP	2002	2643
@NP	Keyvan-Fouladi et al. , 2003	2649
@NP	Keyvan-Fouladi	2649
@NP	et al. , 2003	2664
@NP	et al.	2664
@NP	2003	2672
@NP	Sasaki et al.	2678
@NP	Sasaki	2678
@NP	et al.	2685
@NP	2004 , 2006a	2693
@NP	2004	2693
@NP	2006a	2699
@NP	Claims of the clinical benefits of OECs in spinal cord injury	2707
@NP	Claims	2707
@NP	the clinical benefits of OECs in spinal cord injury	2717
@NP	the clinical benefits	2717
@NP	OECs in spinal cord injury	2742
@NP	OECs	2742
@NP	spinal cord injury	2750
@NP	several clinical centers -LRB- Huang et al. , 2003 ; Amador & Guest , 2005 -RRB-	2787
@NP	several clinical centers	2787
@NP	Huang	2813
@NP	et al. , 2003 ; Amador & Guest , 2005	2819
@NP	et al.	2819
@NP	2003 ; Amador & Guest	2827
@NP	2003	2827
@NP	Amador & Guest	2833
@NP	2005	2849
@NP	these treatments	2865
@NP	rigorous controls and characterization	2887
@NP	the actual cells transplanted	2929
@NP	Dobkin	2960
@NP	et al. , 2006 ; Guest et al. , 2006	2967
@NP	et al.	2967
@NP	2006 ; Guest et al.	2975
@NP	2006	2975
@NP	Guest et al.	2981
@NP	Guest	2981
@NP	et al.	2987
@NP	2006	2995
@NP	its greater accessibility	3013
@NP	the nasal mucosa	3039
@NP	the favored source	3059
@NP	OECs	3081
@NP	autologous transplantation in humans -LRB- Lu et al. , 2001 , 2002 -RRB-	3090
@NP	autologous transplantation	3090
@NP	humans -LRB- Lu et al. , 2001 , 2002 -RRB-	3120
@NP	humans	3120
@NP	Lu	3128
@NP	et al. , 2001 , 2002	3131
@NP	et al.	3131
@NP	2001	3139
@NP	2002	3145
@NP	We	3152
@NP	lamina-propria -LRB- LP -RRB-	3182
@NP	lamina-propria	3182
@NP	LP	3198
@NP	OECs	3210
@NP	the mouse nasal mucosa share several similar properties	3220
@NP	the mouse nasal mucosa share	3220
@NP	those derived from the OB in vitro	3279
@NP	those	3279
@NP	the OB	3298
@NP	Au & Roskams	3315
@NP	2003	3329
@NP	vivo -LRB- Ramer et al. , 2004a ; Richter et al. , 2005 -RRB-	3349
@NP	vivo	3349
@NP	Ramer	3355
@NP	et al. , 2004a ; Richter et al. , 2005	3361
@NP	et al.	3361
@NP	2004a ; Richter et al.	3369
@NP	2004a	3369
@NP	Richter et al.	3376
@NP	Richter	3376
@NP	et al.	3384
@NP	2005	3392
@NP	some differences	3418
@NP	transplantation -LRB- Richter et al. , 2005 -RRB-	3452
@NP	transplantation	3452
@NP	Richter	3469
@NP	et al. , 2005	3477
@NP	et al.	3477
@NP	2005	3485
@NP	only a few rat rubrospinal axons	3501
@NP	mouse LP-OECs but not beyond -LRB- Ramer et al. , 2004a -RRB-	3561
@NP	mouse LP-OECs	3561
@NP	beyond -LRB- Ramer et al. , 2004a -RRB-	3583
@NP	beyond	3583
@NP	Ramer	3591
@NP	et al. , 2004a	3597
@NP	et al.	3597
@NP	2004a	3605
@NP	rat OB-OECs	3632
@NP	brainderived neurotrophic factor -LRB- BDNF ; Ruitenberg et al. , 2003 -RRB-	3659
@NP	brainderived neurotrophic factor	3659
@NP	BDNF ; Ruitenberg et al. , 2003	3693
@NP	BDNF	3693
@NP	Ruitenberg et al. , 2003	3699
@NP	Ruitenberg	3699
@NP	et al. , 2003	3710
@NP	et al.	3710
@NP	2003	3718
@NP	This inability of rubrospinal axons to regenerate	3725
@NP	This inability	3725
@NP	rubrospinal axons	3743
@NP	part	3792
@NP	a weakness	3801
@NP	the intrinsic cell body response	3815
@NP	the red nucleus -LRB- Tetzlaff et al. , 1991 ; Jenkins et al. , 1993 -RRB-	3851
@NP	the red nucleus	3851
@NP	Tetzlaff	3868
@NP	et al. , 1991 ; Jenkins et al. , 1993	3877
@NP	et al.	3877
@NP	1991 ; Jenkins et al.	3885
@NP	1991	3885
@NP	Jenkins et al.	3891
@NP	Jenkins	3891
@NP	et al.	3899
@NP	1993	3907
@NP	We	3914
@NP	cell body treatment of the red nucleus with BDNF	3944
@NP	cell body treatment	3944
@NP	the red nucleus with BDNF	3967
@NP	the red nucleus	3967
@NP	BDNF	3988
@NP	the atrophy of rubrospinal neurons	4003
@NP	the atrophy	4003
@NP	rubrospinal neurons	4018
@NP	the expression of regeneration - associated genes	4050
@NP	the expression	4050
@NP	regeneration - associated genes	4068
@NP	regeneration	4068
@NP	genes	4093
@NP	axonal regeneration of the rubrospinal axons	4112
@NP	axonal regeneration	4112
@NP	the rubrospinal axons	4135
@NP	free-ending peripheral nerve transplants	4162
@NP	the cervical spinal cord injury site -LRB- Kobayashi et al. , 1997 -RRB-	4216
@NP	the cervical spinal cord injury site	4216
@NP	Kobayashi	4254
@NP	et al. , 1997	4264
@NP	et al.	4264
@NP	1997	4272
@NP	This strategy	4279
@NP	1 year	4334
@NP	spinal cord injury -LRB- Kwon et al. , 2002 -RRB-	4347
@NP	spinal cord injury	4347
@NP	Kwon	4367
@NP	et al. , 2002	4372
@NP	et al.	4372
@NP	2002	4380
@NP	We	4387
@NP	a BDNF-induced enhancement in the rubrospinal cell body response	4418
@NP	a BDNF-induced enhancement	4418
@NP	the rubrospinal cell body response	4448
@NP	regeneration of rubrospinal axons	4497
@NP	regeneration	4497
@NP	rubrospinal axons	4513
@NP	a LP-OEC transplant	4547
@NP	functional recovery	4586
@NP	the forelimb following a cervical lesion of the spinal cord	4609
@NP	the forelimb	4609
@NP	a cervical lesion of the spinal cord	4632
@NP	a cervical lesion	4632
@NP	the spinal cord	4653
@NP	this	4680
@NP	we	4686
@NP	a transplant	4698
@NP	highly enriched preparations	4714
@NP	LP-OECs derived from the nasal mucosa of green fluorescent protein	4746
@NP	LP-OECs	4746
@NP	the nasal mucosa of green fluorescent protein	4767
@NP	the nasal mucosa	4767
@NP	green fluorescent protein	4787
@NP	GFP	4814
@NP	neonatal mice	4830
@NP	a cell body treatment of the red nucleus delivering BDNF for 2 weeks	4849
@NP	a cell body treatment	4849
@NP	the red nucleus delivering BDNF for 2 weeks	4874
@NP	the red nucleus	4874
@NP	BDNF for 2 weeks	4901
@NP	BDNF	4901
@NP	2 weeks	4910
@NP	This combinatorial approach	4919
@NP	some	4956
@NP	rubrospinal axons	4987
@NP	their regeneration	5027
@NP	LP-OECs	5064
@NP	this combined strategy	5087
@NP	the functional recovery	5133
@NP	the injured forelimb , which correlated with decreased sensory thresholds	5160
@NP	the injured forelimb	5160
@NP	decreased sensory thresholds	5204
@NP	Materials and methods Preparation of LP-OECs from GFP	5235
@NP	Materials	5235
@NP	methods Preparation of LP-OECs from GFP	5249
@NP	methods Preparation	5249
@NP	LP-OECs from GFP	5272
@NP	LP-OECs	5272
@NP	GFP	5285
@NP	transgenic mice The preparation of OECs is detailed elsewhere	5289
@NP	transgenic mice	5289
@NP	The preparation of OECs	5305
@NP	The preparation	5305
@NP	OECs	5324
@NP	Ramer et al. , 2004a	5352
@NP	Ramer	5352
@NP	et al.	5358
@NP	2004a	5366
@NP	brief	5377
@NP	OECs	5384
@NP	the olfactory mucosa of postnatal day 5 transgenic mice	5409
@NP	the olfactory mucosa	5409
@NP	postnatal day 5 transgenic mice	5433
@NP	decapitation	5476
@NP	GFP	5501
@NP	the beta-actin promoter	5511
@NP	Au & Roskams , 2003 ; Ramer et al. , 2004a ; Richter et al. , 2005	5536
@NP	Au & Roskams	5536
@NP	2003 ; Ramer et al. , 2004a ; Richter et al.	5548
@NP	2003	5548
@NP	Ramer et al. , 2004a ; Richter et al.	5554
@NP	Ramer	5554
@NP	et al. , 2004a ; Richter et al.	5560
@NP	et al. , 2004a	5560
@NP	et al.	5560
@NP	2004a	5568
@NP	Richter et al.	5575
@NP	Richter	5575
@NP	et al.	5583
@NP	2005	5591
@NP	Initial plating	6033
@NP	MEM-Dvaline	6052
@NP	10 % fetal bovine serum -LRB- FBS -RRB-	6065
@NP	10 % fetal bovine serum	6065
@NP	FBS	6089
@NP	100 U ⁄ mL penicillin ⁄ streptomycin -LRB- P ⁄ S -RRB-	6098
@NP	100 U ⁄ mL penicillin ⁄ streptomycin	6098
@NP	P ⁄ S	6136
@NP	a poly-l-lysine substrate without additional mitogens	6148
@NP	a poly-l-lysine substrate	6148
@NP	additional mitogens	6182
@NP	4	6215
@NP	5 days	6217
@NP	enrichment performed using anti-Thy1.1-mediated complement lysis	6233
@NP	enrichment	6233
@NP	anti-Thy1.1-mediated complement lysis	6260
@NP	the majority of contaminating fibroblasts	6308
@NP	the majority	6308
@NP	contaminating fibroblasts	6324
@NP	Cells	6351
@NP	DMEM ⁄ F-12 , 10 % FBS and 100 U ⁄ mL P ⁄ S	6374
@NP	DMEM ⁄ F-12	6374
@NP	10 % FBS and 100 U ⁄ mL P ⁄ S	6386
@NP	10 % FBS	6386
@NP	100 U ⁄ mL P ⁄ S	6398
@NP	100 U ⁄ mL P	6398
@NP	⁄ S	6411
@NP	an additional 4	6439
@NP	6 days	6455
@NP	they	6468
@NP	Thy1 .1	6497
@NP	complement lysis	6514
@NP	the same media for an additional 24	6544
@NP	the same media	6544
@NP	an additional 24	6563
@NP	48 h	6580
@NP	transplantation	6594
@NP	a subset of cells	6625
@NP	a subset	6625
@NP	cells	6637
@NP	plastic coverslips	6661
@NP	antigenic assessment	6694
@NP	the same time as harvesting for transplantation	6718
@NP	the same time	6718
@NP	harvesting for transplantation	6735
@NP	harvesting	6735
@NP	transplantation	6750
@NP	They	6767
@NP	as at least 75 % double immunopositive	6786
@NP	as at least 75 %	6786
@NP	p75	6828
@NP	glial fibrillary acidic protein -LRB- GFAP -RRB-	6836
@NP	glial fibrillary acidic protein	6836
@NP	GFAP	6869
@NP	hence the fibroblast portion	6876
@NP	fibronectin + ⁄	6918
@NP	fibronectin	6918
@NP	⁄	6931
@NP	25 %	6962
@NP	these culture conditions	6973
@NP	density of plating media , composition of plating media and plating substrate	6999
@NP	density	6999
@NP	media , composition of plating media	7018
@NP	media	7018
@NP	composition of plating media	7025
@NP	composition	7025
@NP	plating media	7040
@NP	substrate	7066
@NP	we	7077
@NP	OECs	7108
@NP	Schwann cells	7137
@NP	Richter & Roskams	7171
@NP	2008	7190
@NP	the dissected nasal mucosa	7206
@NP	a small percentage	7245
@NP	Schwann cells	7267
@NP	cranial nerves	7294
@NP	identical conditions	7330
@NP	Schwann cells	7361
@NP	OECs	7411
@NP	very different morphologies , mitosis and migration capabilities	7432
@NP	very different morphologies	7432
@NP	mitosis	7461
@NP	migration capabilities	7473
@NP	any significant representation of Schwann cell contamination	7503
@NP	any significant representation	7503
@NP	Schwann cell contamination	7537
@NP	visual inspection	7587
@NP	we	7615
@NP	a few	7635
@NP	Schwann cells	7655
@NP	sensory nerves in the mucosa	7674
@NP	sensory nerves	7674
@NP	the mucosa	7692
@NP	this contribution	7704
@NP	LP-OECs	7734
@NP	a density of 5600 cells ⁄ cm2 into T75 flasks for transplantation	7757
@NP	a density	7757
@NP	5600 cells ⁄ cm2 into T75 flasks for transplantation	7770
@NP	5600 cells	7770
@NP	cm2	7783
@NP	T75 flasks for transplantation	7792
@NP	T75 flasks	7792
@NP	transplantation	7807
@NP	transplantation	7831
@NP	the cells from one T75 flask of LP-OECs	7848
@NP	the cells	7848
@NP	one T75 flask of LP-OECs	7863
@NP	one T75 flask	7863
@NP	LP-OECs	7880
@NP	0.25 % trypsin ⁄ 1 %	7908
@NP	0.25 % trypsin ⁄	7908
@NP	EDTA , followed by washing in phosphate-buffered saline -LRB- PBS -RRB-	7927
@NP	EDTA	7927
@NP	phosphate-buffered saline -LRB- PBS -RRB-	7956
@NP	phosphate-buffered saline	7956
@NP	PBS	7983
@NP	resuspension at a concentration of 100 000 -- 120 000 cells	7992
@NP	resuspension	7992
@NP	a concentration of 100 000 -- 120 000 cells	8008
@NP	a concentration	8008
@NP	100 000 -- 120 000 cells	8027
@NP	100 000	8027
@NP	120 000 cells	8035
@NP	µL in DMEM ⁄ F-12	8051
@NP	µL	8051
@NP	DMEM ⁄ F-12	8057
@NP	The total time from dissection to transplantation	8069
@NP	The total time	8069
@NP	dissection to transplantation	8089
@NP	dissection	8089
@NP	transplantation	8103
@NP	11 to 14 days	8131
@NP	initial experiments	8163
@NP	fresh prepared OECs	8192
@NP	maintenance of phenotype	8222
@NP	maintenance	8222
@NP	phenotype	8237
@NP	cryopreservation of cells -LRB- Ramer et al. , 2004a ; and this study -RRB-	8253
@NP	cryopreservation	8253
@NP	cells -LRB- Ramer et al. , 2004a ; and this study -RRB-	8273
@NP	cells	8273
@NP	Ramer	8280
@NP	et al. , 2004a ; and this study	8286
@NP	et al.	8286
@NP	2004a	8294
@NP	this study	8305
@NP	some experiments	8318
@NP	OECs that were cryopreserved	8340
@NP	OECs	8340
@NP	Spinal cord injury and treatment Animal procedures	8370
@NP	Spinal cord injury	8370
@NP	treatment Animal procedures	8393
@NP	accordance	8439
@NP	the guidelines of the Canadian Council for Animal Care	8455
@NP	the guidelines	8455
@NP	the Canadian Council for Animal Care	8473
@NP	the Canadian Council	8473
@NP	Animal Care	8498
@NP	the Animal Care Committee of the University of British Columbia	8531
@NP	the Animal Care Committee	8531
@NP	the University of British Columbia	8560
@NP	the University	8560
@NP	British Columbia	8578
@NP	A total of 28 out of 32 animals	8596
@NP	A total	8596
@NP	28	8607
@NP	32 animals	8617
@NP	behavioral and histological analysis	8642
@NP	Dorsolateral funiculus crush Thirty-two adult male Sprague -- Dawley rats	8680
@NP	Dorsolateral funiculus crush	8680
@NP	Thirty-two adult male Sprague -- Dawley rats	8709
@NP	Dawley	8739
@NP	300 -- 400 g	8752
@NP	300	8752
@NP	400 g	8756
@NP	cyclosporine A	8790
@NP	10 mg ⁄ kg per day , i.p. ; Novartis Pharmaceuticals , Mississauga , ON , Canada	8806
@NP	10 mg ⁄ kg	8806
@NP	day , i.p. ; Novartis Pharmaceuticals , Mississauga , ON , Canada	8821
@NP	day , i.p.	8821
@NP	day	8821
@NP	Novartis Pharmaceuticals , Mississauga , ON , Canada	8832
@NP	2 days	8883
@NP	surgery and each day	8897
@NP	surgery	8897
@NP	each day	8909
@NP	the duration of the experiment	8922
@NP	the duration	8922
@NP	the experiment	8938
@NP	Rats	8954
@NP	a mixture	8982
@NP	ketamine hydrochloride	8995
@NP	70 mg ⁄ kg , i.p. ; Bimeda-MTC , Cambridge , ON , Canada	9019
@NP	70 mg	9019
@NP	⁄ kg , i.p. ; Bimeda-MTC , Cambridge , ON , Canada	9025
@NP	⁄ kg , i.p.	9025
@NP	⁄ kg	9025
@NP	Bimeda-MTC , Cambridge , ON , Canada	9037
@NP	xylazine hydrochloride	9076
@NP	10 mg ⁄ kg i.p. ; Bayer , Etobicoke , ON , Canada	9100
@NP	10 mg	9100
@NP	⁄ kg i.p. ; Bayer , Etobicoke , ON , Canada	9106
@NP	⁄ kg i.p.	9106
@NP	⁄ kg	9106
@NP	Bayer , Etobicoke , ON , Canada	9117
@NP	a laminectomy	9148
@NP	the left side	9179
@NP	the fourth and fifth cervical segments	9203
@NP	the fourth	9203
@NP	fifth cervical segments	9218
@NP	The dura	9243
@NP	microscissors	9265
@NP	the spinal cord	9289
@NP	the dorsolateral funiculus	9309
@NP	the rubrospinal tract	9346
@NP	20 s with custom-designed fine surgical forceps at a depth of 2 mm	9384
@NP	20 s	9384
@NP	custom-designed fine surgical forceps at a depth of 2 mm	9394
@NP	custom-designed fine surgical forceps	9394
@NP	a depth of 2 mm	9435
@NP	a depth	9435
@NP	2 mm	9446
@NP	Ramer	9491
@NP	et al. , 2004a ; Richter et al. , 2005	9497
@NP	et al.	9497
@NP	2004a ; Richter et al.	9505
@NP	2004a	9505
@NP	Richter et al.	9512
@NP	Richter	9512
@NP	et al.	9520
@NP	2005	9528
@NP	The distal blades of # 5 Dumont forceps	9535
@NP	The distal blades	9535
@NP	# 5 Dumont forceps	9556
@NP	a width of 0.2 mm	9592
@NP	a width	9592
@NP	0.2 mm	9603
@NP	the length of exactly 2 mm	9614
@NP	the length	9614
@NP	exactly 2 mm	9628
@NP	a reproducible insertion of a fine tip	9651
@NP	a reproducible insertion	9651
@NP	a fine tip	9679
@NP	the desired depth of 2 mm -LRB- see also Plunet et al. , 2008 -RRB-	9693
@NP	the desired depth	9693
@NP	2 mm -LRB- see also Plunet et al. , 2008 -RRB-	9714
@NP	2 mm	9714
@NP	Plunet	9729
@NP	et al. , 2008	9736
@NP	et al.	9736
@NP	2008	9744
@NP	Cell transplantation LP-OECs	9751
@NP	the spinal cord	9803
@NP	Ramer	9844
@NP	et al. , 2004a ; Richter et al. , 2005	9850
@NP	et al.	9850
@NP	2004a ; Richter et al.	9858
@NP	2004a	9858
@NP	Richter et al.	9865
@NP	Richter	9865
@NP	et al.	9873
@NP	2005	9881
@NP	LP-OEC slurries in DMEM ⁄ F-12	9888
@NP	LP-OEC slurries	9888
@NP	DMEM ⁄ F-12	9907
@NP	the pulled glass pipette with a diameter of 60	9934
@NP	the pulled glass pipette	9934
@NP	a diameter of 60	9964
@NP	a diameter	9964
@NP	60	9978
@NP	80 µm attached to a Hamilton syringe	9981
@NP	80 µm	9981
@NP	a Hamilton syringe	9999
@NP	OECs	10019
@NP	1 mm rostral and caudal	10059
@NP	1 mm rostral	10059
@NP	caudal	10076
@NP	the lesion site	10086
@NP	the suspension	10112
@NP	these two points	10143
@NP	A total of 1.5 µL of cell slurry	10161
@NP	A total	10161
@NP	1.5 µL of cell slurry	10172
@NP	1.5 µL	10172
@NP	cell slurry	10182
@NP	each rat	10216
@NP	a total of 150 000	10234
@NP	a total	10234
@NP	150 000	10245
@NP	180 000 cells	10253
@NP	Control animals	10268
@NP	the same volume of DMEM ⁄ F-12	10293
@NP	the same volume	10293
@NP	DMEM ⁄ F-12	10312
@NP	the same sites	10335
@NP	the same rate	10357
@NP	The glass pipette	10372
@NP	place for 5 min	10402
@NP	place	10402
@NP	5 min	10412
@NP	each injection	10424
@NP	cells	10454
@NP	the spinal cord	10472
@NP	the syringe	10516
@NP	injection	10535
@NP	the pipette	10546
@NP	the muscle	10582
@NP	the skin	10610
@NP	wound clips	10631
@NP	Cell body treatment BDNF or vehicle	10644
@NP	Cell body treatment BDNF	10644
@NP	vehicle	10672
@NP	2 weeks	10696
@NP	a cannula	10708
@NP	the vicinity of the red nucleus	10742
@NP	the vicinity	10742
@NP	the red nucleus	10758
@NP	Kobayashi	10800
@NP	et al. , 1997 ; Kwon et al. , 2002	10810
@NP	et al.	10810
@NP	1997 ; Kwon et al.	10818
@NP	1997	10818
@NP	Kwon et al.	10824
@NP	Kwon	10824
@NP	et al.	10829
@NP	2002	10837
@NP	brief	10847
@NP	cell transplantation -LRB- while the rats were still anesthetized as above -RRB-	10860
@NP	cell transplantation	10860
@NP	the rats	10888
@NP	a 28	10932
@NP	gage cannula	10938
@NP	silastic tubing	10964
@NP	an osmotic minipump	10983
@NP	Alzet no. 2002 , 0.5 µL ⁄ h ; Alzet , Palo Alto , CA , USA	11004
@NP	Alzet no. 2002	11004
@NP	Alzet	11004
@NP	2002	11014
@NP	0.5 µL ⁄ h ; Alzet , Palo Alto	11020
@NP	0.5 µL ⁄ h	11020
@NP	0.5 µL	11020
@NP	⁄ h	11027
@NP	Alzet , Palo Alto	11032
@NP	Alzet	11032
@NP	Palo Alto	11039
@NP	CA , USA	11050
@NP	CA	11050
@NP	USA	11054
@NP	6.3 mm posterior to Bregma	11088
@NP	6.3 mm posterior	11088
@NP	Bregma	11108
@NP	1.7 mm lateral -LRB- right -RRB- of midline	11116
@NP	1.7 mm lateral -LRB- right -RRB-	11116
@NP	1.7 mm lateral	11116
@NP	right	11132
@NP	midline	11142
@NP	6.5 mm	11154
@NP	the dura	11171
@NP	Animals treated with BDNF	11181
@NP	Animals	11181
@NP	BDNF	11202
@NP	0.5 lg	11216
@NP	⁄ µL ⁄ h of BDNF	11223
@NP	⁄ µL	11223
@NP	⁄ h of BDNF	11228
@NP	⁄ h	11228
@NP	BDNF	11235
@NP	gift from Regeneron Pharmaceuticals , Tarrytown , NY ,	11241
@NP	gift	11241
@NP	Regeneron Pharmaceuticals , Tarrytown , NY ,	11251
@NP	USA	11293
@NP	a vehicle solution of 20 mm sterile PBS	11301
@NP	a vehicle solution	11301
@NP	20 mm sterile PBS	11323
@NP	20 mm	11323
@NP	100 U of P ⁄ S and 0.5 % rat serum albumin -LRB- Sigma-Aldrich ; no	11342
@NP	100 U of P ⁄ S	11342
@NP	100 U	11342
@NP	P ⁄ S	11351
@NP	0.5 % rat serum albumin -LRB- Sigma-Aldrich ; no	11361
@NP	0.5 %	11361
@NP	rat serum albumin -LRB- Sigma-Aldrich ; no	11366
@NP	rat serum albumin	11366
@NP	Sigma-Aldrich ; no	11385
@NP	Sigma-Aldrich	11385
@NP	no	11400
@NP	A-6272	11404
@NP	Animals treated with vehicle	11413
@NP	Animals	11413
@NP	vehicle	11434
@NP	the vehicle solution	11451
@NP	insertion	11485
@NP	the cannula and insertion of the osmotic minipump under the skin of the neck	11498
@NP	the cannula and insertion	11498
@NP	the osmotic minipump under the skin of the neck	11527
@NP	the osmotic minipump	11527
@NP	the skin of the neck	11554
@NP	the skin	11554
@NP	the neck	11566
@NP	the skin	11576
@NP	wound clips	11601
@NP	Fig. 1 and Table 1 for the experimental design and more details	11618
@NP	Fig. 1	11618
@NP	Table 1 for the experimental design and more details	11629
@NP	Table 1	11629
@NP	the experimental design and more details	11641
@NP	the experimental design	11641
@NP	more details	11669
@NP	Behavioral testing Cylinder test Forelimb usage	11683
@NP	Behavioral testing Cylinder	11683
@NP	test Forelimb usage	11711
@NP	a clear Plexiglas cylinder -LRB- 20 cm in diameter and 30 cm high -RRB-	11749
@NP	a clear Plexiglas cylinder	11749
@NP	20 cm in diameter and 30 cm	11777
@NP	20 cm	11777
@NP	diameter and 30 cm	11786
@NP	diameter	11786
@NP	30 cm	11799
@NP	5 min -LRB- Liu et al. , 1999 -RRB-	11815
@NP	5 min	11815
@NP	Liu	11822
@NP	et al. , 1999	11826
@NP	et al.	11826
@NP	1999	11834
@NP	The cylinder	11841
@NP	rats	11865
@NP	their forelimbs	11877
@NP	vertical exploration	11897
@NP	A mirror	11919
@NP	the cylinder	11946
@NP	scoring of movements from all viewpoints	11969
@NP	scoring	11969
@NP	movements from all viewpoints	11980
@NP	movements	11980
@NP	all viewpoints	11995
@NP	The behavior	12011
@NP	frame	12035
@NP	frame	12044
@NP	a later time-point	12053
@NP	a blinded rater	12075
@NP	Forelimb use	12092
@NP	independent use of the left injured forelimb	12119
@NP	independent use	12119
@NP	the left injured forelimb	12138
@NP	independent use of the right forelimb	12165
@NP	independent use	12165
@NP	the right forelimb	12184
@NP	concomitant use of	12207
@NP	concomitant use	12207
@NP	forelimbs for contacting the wall of the cylinder during a full rear	12231
@NP	forelimbs	12231
@NP	the wall of the cylinder	12256
@NP	the wall	12256
@NP	the cylinder	12268
@NP	a full rear	12288
@NP	a more accurate use of the left forelimb	12312
@NP	a more accurate use	12312
@NP	the left forelimb	12335
@NP	the score	12354
@NP	a percentage use	12381
@NP	the ` left and both ' forelimbs	12401
@NP	the total number of left , right and both forelimb use	12443
@NP	the total number	12443
@NP	left , right and both forelimb use	12463
@NP	left	12463
@NP	right	12469
@NP	both forelimb use	12479
@NP	Food-pellet reaching task The food-pellet reaching task used	12498
@NP	Food-pellet	12498
@NP	task	12519
@NP	The food-pellet	12524
@NP	task used	12549
@NP	task	12549
@NP	Whishaw	12575
@NP	et al. -LRB- 1993 -RRB-	12583
@NP	et al.	12583
@NP	1993	12591
@NP	Chan et al. , 2005	12627
@NP	Chan	12627
@NP	et al.	12632
@NP	2005	12640
@NP	brief	12650
@NP	the rats	12657
@NP	injury	12686
@NP	a 1-cm opening a food pellet placed in a dimple 2 cm away	12710
@NP	a 1-cm	12710
@NP	a food pellet placed in a dimple 2 cm away	12725
@NP	a food pellet	12725
@NP	a dimple 2 cm away	12749
@NP	a dimple	12749
@NP	2 cm	12758
@NP	The behavior	12769
@NP	a 10-point scale	12796
@NP	the execution of sequential aspects	12825
@NP	the execution	12825
@NP	sequential aspects	12842
@NP	score 3	12875
@NP	score 5	12895
@NP	score 7	12920
@NP	a food pellet	12929
@NP	details , see Chan et al. , 2005	12948
@NP	details	12948
@NP	Chan	12961
@NP	et al. , 2005	12966
@NP	et al.	12966
@NP	2005	12974
@NP	Sensory tests The sensory testing	12981
@NP	Sensory tests	12981
@NP	The sensory testing	12995
@NP	Ramer et al. , 2004b	13044
@NP	Ramer	13044
@NP	et al.	13050
@NP	2004b	13058
@NP	The thermal threshold of forepaws	13066
@NP	The thermal threshold	13066
@NP	forepaws	13091
@NP	the plantar tester -LRB- Ugo Basile , Italy -RRB-	13122
@NP	the plantar tester	13122
@NP	Ugo Basile	13142
@NP	Italy	13154
@NP	Rats	13162
@NP	a designed cage in a glass floor over a moveable infrared generator	13182
@NP	a designed cage	13182
@NP	a glass floor over a moveable infrared generator	13201
@NP	a glass floor	13201
@NP	a moveable infrared generator	13220
@NP	The infrared source	13251
@NP	The	13251
@NP	source	13264
@NP	the center of the palmar forepaw	13292
@NP	the center	13292
@NP	the palmar forepaw	13306
@NP	The time from stimulus onset to withdrawal	13326
@NP	The time	13326
@NP	stimulus onset to withdrawal	13340
@NP	stimulus onset	13340
@NP	withdrawal	13358
@NP	both forepaws	13386
@NP	Mechanical threshold of forepaws	13401
@NP	Mechanical threshold	13401
@NP	forepaws	13425
@NP	the plantar aesthesiometer -LRB- Ugo Basile , Italy -RRB-	13458
@NP	the plantar aesthesiometer	13458
@NP	Ugo Basile	13486
@NP	Italy	13498
@NP	Rats	13506
@NP	a raised cage with a wire mesh floor over the stimulator unit	13526
@NP	a raised cage	13526
@NP	a wire mesh floor over the stimulator unit	13545
@NP	a wire mesh floor	13545
@NP	the stimulator unit	13568
@NP	The vertical metal filament	13589
@NP	the center of the palmar surface of the forepaw	13632
@NP	the center	13632
@NP	the palmar surface of the forepaw	13646
@NP	the palmar surface	13646
@NP	the forepaw	13668
@NP	force	13692
@NP	1 to 50 g over 7 s.	13717
@NP	1 to 50 g	13717
@NP	7 s.	13732
@NP	Force and latency at withdrawal	13737
@NP	Force	13737
@NP	latency at withdrawal	13747
@NP	latency	13747
@NP	withdrawal	13758
@NP	both forepaws	13787
@NP	both sensory tests	13806
@NP	rats	13826
@NP	weekly two -- three times for each paw for 2 -- 3 weeks	13843
@NP	weekly two -- three times for each paw for 2 --	13843
@NP	weekly two	13843
@NP	three times for each paw for 2	13854
@NP	three times	13854
@NP	each paw for 2	13870
@NP	each paw	13870
@NP	2	13883
@NP	3 weeks	13885
@NP	injury	13900
@NP	a control baseline	13917
@NP	4 weeks	13945
@NP	injury and treatment	13959
@NP	Baseline behavior	13981
@NP	surgery	14019
@NP	all animals	14032
@NP	4 weeks	14067
@NP	injury and treatment	14081
@NP	rats	14112
@NP	the food-pellet	14128
@NP	task	14153
@NP	any influences	14173
@NP	other behavioral tests	14191
@NP	all rats	14215
@NP	a week the night	14241
@NP	a week	14241
@NP	the night	14248
@NP	the testing day	14268
@NP	rubrospinal axons and immunocytochemistry Anterograde labeling	14297
@NP	rubrospinal axons	14363
@NP	Five weeks	14381
@NP	spinal cord injury and treatment	14398
@NP	spinal cord injury	14398
@NP	treatment	14421
@NP	rats	14432
@NP	a mixture	14460
@NP	ketamine hydrochloride	14473
@NP	70 mg ⁄ kg , i.p. ; Bimeda-MTC , Cambridge , ON , Canada	14497
@NP	70 mg	14497
@NP	⁄ kg , i.p. ; Bimeda-MTC , Cambridge , ON , Canada	14503
@NP	⁄ kg , i.p.	14503
@NP	⁄ kg	14503
@NP	Bimeda-MTC , Cambridge , ON , Canada	14515
@NP	xylazine hydrochloride	14554
@NP	10 mg ⁄ kg i.p. ; Bayer , Etobicoke , ON , Canada	14578
@NP	10 mg	14578
@NP	⁄ kg i.p. ; Bayer , Etobicoke , ON , Canada	14584
@NP	⁄ kg i.p.	14584
@NP	⁄ kg	14584
@NP	Bayer , Etobicoke , ON , Canada	14595
@NP	placed in a Kopf stereotaxic frame	14630
@NP	a Kopf	14640
@NP	dextran amine	14679
@NP	BDA ; 10 000 kDa molecular mass	14694
@NP	BDA	14694
@NP	10 000 kDa molecular mass	14699
@NP	10 000	14699
@NP	kDa molecular mass	14706
@NP	10 % in sterile water	14726
@NP	10 %	14726
@NP	sterile water	14733
@NP	Molecular Probes	14748
@NP	Eugene	14766
@NP	OR , USA	14774
@NP	OR	14774
@NP	USA	14778
@NP	the red nucleus at a rate of 30 nL	14817
@NP	the red nucleus	14817
@NP	a rate of 30 nL	14836
@NP	a rate	14836
@NP	30 nL	14846
@NP	⁄ min	14852
@NP	a pulled glass pipette -LRB- diameter of 20 µm -RRB- glued to a Hamilton syringe	14867
@NP	a pulled glass pipette -LRB- diameter of 20 µm -RRB-	14867
@NP	a pulled glass pipette	14867
@NP	diameter of 20 µm	14891
@NP	diameter	14891
@NP	20 µm	14903
@NP	a Hamilton syringe	14919
@NP	Coordinates	14939
@NP	6.1 mm posterior	14956
@NP	Bregma , 0.7 mm lateral -LRB- right -RRB- of midline	14976
@NP	Bregma	14976
@NP	0.7 mm lateral -LRB- right -RRB- of midline	14984
@NP	0.7 mm lateral -LRB- right -RRB-	14984
@NP	0.7 mm lateral	14984
@NP	right	15000
@NP	midline	15010
@NP	7 mm	15022
@NP	the dura	15037
@NP	The pipette	15047
@NP	place for 10 min	15071
@NP	place	15071
@NP	10 min	15081
@NP	injection	15094
@NP	BDA	15119
@NP	the syringe	15146
@NP	Immunocytochemistry	15159
@NP	Six weeks	15179
@NP	injury and treatment	15195
@NP	rats	15217
@NP	a lethal dose of chloral hydrate	15245
@NP	a lethal dose	15245
@NP	chloral hydrate	15262
@NP	100 mg ⁄ kg , i.p. ; BDH Chemicals , Toronto , ON , Canada	15279
@NP	100 mg	15279
@NP	⁄ kg , i.p. ; BDH Chemicals , Toronto , ON , Canada	15286
@NP	⁄ kg , i.p.	15286
@NP	⁄ kg	15286
@NP	BDH Chemicals , Toronto , ON , Canada	15298
@NP	BDH Chemicals	15298
@NP	Toronto , ON , Canada	15313
@NP	PBS	15367
@NP	phosphate-buffered , 4 % paraformaldehyde -LRB- pH 7.4 -RRB-	15383
@NP	phosphate-buffered , 4 % paraformaldehyde	15383
@NP	pH 7.4	15424
@NP	The midbrain , cerebellum and cervical spinal cords	15433
@NP	The midbrain	15433
@NP	cerebellum	15447
@NP	cervical spinal cords	15462
@NP	4 % paraformaldehyde	15513
@NP	24 % sucrose in 0.1 m phosphate buffer over 2 -- 3 days	15561
@NP	24 % sucrose in 0.1 m phosphate buffer over 2	15561
@NP	24 % sucrose	15561
@NP	0.1 m phosphate buffer over 2	15576
@NP	0.1 m phosphate buffer	15576
@NP	2	15604
@NP	3 days	15606
@NP	isopentane over dry ice	15628
@NP	isopentane	15628
@NP	dry ice	15644
@NP	Spinal cords	15653
@NP	20-µm sections	15680
@NP	a cryostat	15698
@NP	80 °C	15724
@NP	Cervical segments C2 and C7	15730
@NP	Cervical segments C2	15730
@NP	C7	15755
@NP	20-µm sections in the coronal plane	15772
@NP	20-µm sections	15772
@NP	the coronal plane	15790
@NP	Cervical segments from C3 to C6	15809
@NP	Cervical segments	15809
@NP	C3 to C6	15832
@NP	C3	15832
@NP	C6	15838
@NP	20-µm longitudinal sections in the horizontal plane	15855
@NP	20-µm longitudinal sections	15855
@NP	the horizontal plane	15886
@NP	frozen sections	15923
@NP	a slide warmer for 30 min	15954
@NP	a slide warmer	15954
@NP	30 min	15973
@NP	10 mm PBS three times for 5 min	15995
@NP	10 mm PBS	15995
@NP	three times	16005
@NP	5 min	16021
@NP	10 % normal donkey serum -LRB- in 0.1 % Triton X-100 -RRB-	16047
@NP	10 % normal donkey serum	16047
@NP	10 %	16047
@NP	in 0.1 % Triton X-100	16072
@NP	0.1 %	16075
@NP	Triton X-100	16080
@NP	Triton	16080
@NP	X-100	16087
@NP	30 min	16098
@NP	nonspecific binding	16116
@NP	All primary antibodies	16752
@NP	24 h at room temperature	16792
@NP	24 h	16792
@NP	room temperature	16800
@NP	Secondary antibodies -LRB- 1 : 200 , Jackson -RRB-	16818
@NP	Secondary antibodies	16818
@NP	1 : 200 , Jackson	16840
@NP	1 : 200	16840
@NP	Jackson	16849
@NP	donkey	16868
@NP	Alexa 350 , Alexa 488 and Cy3	16890
@NP	Alexa 350	16890
@NP	Alexa 488	16901
@NP	Cy3	16915
@NP	2	16941
@NP	3 h at room temperature	16943
@NP	3 h	16943
@NP	room temperature	16950
@NP	BDA	16968
@NP	Cy3	16996
@NP	AMCA-conjugated streptavidin -LRB- 1 : 400 , Jackson -RRB- applied for 2	17004
@NP	AMCA-conjugated streptavidin -LRB- 1 : 400 , Jackson -RRB-	17004
@NP	AMCA-conjugated streptavidin	17004
@NP	1 : 400 , Jackson	17034
@NP	1 : 400	17034
@NP	Jackson	17043
@NP	2	17064
@NP	3 h at room temperature	17066
@NP	3 h	17066
@NP	room temperature	17073
@NP	Sections	17091
@NP	glycerol mounting liquid -LRB- Sigma -RRB-	17121
@NP	glycerol mounting liquid	17121
@NP	Sigma	17147
@NP	Image analysis and quantification Images	17155
@NP	an Axioplan 2 microscope -LRB- Zeiss , Jena , Germany -RRB-	17225
@NP	an Axioplan 2 microscope	17225
@NP	Zeiss	17251
@NP	Jena	17258
@NP	Germany	17264
@NP	a digital camera -LRB- QImaging , Burnaby , BC , Canada -RRB-	17274
@NP	a digital camera	17274
@NP	QImaging	17292
@NP	Burnaby	17302
@NP	BC , Canada	17311
@NP	Northern Eclipse software -LRB- Empix Imaging , Mississauga , ON , Canada -RRB-	17327
@NP	Northern Eclipse software	17327
@NP	Empix Imaging	17354
@NP	Mississauga	17369
@NP	ON , Canada	17382
@NP	Digital images	17395
@NP	Photoshop 7.0	17439
@NP	Adobe Systems	17454
@NP	San Jose	17469
@NP	CA , USA	17479
@NP	SigmaScan Pro -LRB- SPSS , Chicago , IL , USA -RRB-	17489
@NP	SigmaScan	17489
@NP	Pro -LRB- SPSS , Chicago , IL , USA -RRB-	17499
@NP	Pro	17499
@NP	SPSS , Chicago	17504
@NP	IL	17519
@NP	USA	17523
@NP	Matlab 6.5 -LRB- The MathWorks , Natick , MA , USA -RRB- softwares	17532
@NP	Matlab 6.5	17532
@NP	The MathWorks	17544
@NP	Natick	17559
@NP	MA , USA	17567
@NP	softwares	17576
@NP	The number of rubrospinal axons	17587
@NP	The number	17587
@NP	rubrospinal axons	17601
@NP	each animal	17638
@NP	the number of BDA-traced axons	17663
@NP	the number	17663
@NP	BDA-traced axons	17677
@NP	three cross-sections at C2	17697
@NP	three cross-sections	17697
@NP	C2	17721
@NP	Rubrospinal regeneration	17725
@NP	the presence	17780
@NP	traced axons	17796
@NP	the spinal cord	17820
@NP	every other 20 µm in longitudinal -LRB- horizontal -RRB- sections	17836
@NP	every other 20 µm	17836
@NP	longitudinal -LRB- horizontal -RRB- sections	17857
@NP	we	17896
@NP	any evidence for axonal regeneration	17912
@NP	any evidence	17912
@NP	axonal regeneration	17929
@NP	we	17950
@NP	each animal	17977
@NP	the distance	17989
@NP	the terminal ends	18010
@NP	the most caudal five rubrospinal axon tips and the lesion epicenter	18031
@NP	five rubrospinal axon tips and the lesion epicenter	18047
@NP	five rubrospinal axon tips	18047
@NP	the lesion epicenter	18078
@NP	the three best	18105
@NP	longitudinal sections of the rubrospinal tract	18127
@NP	longitudinal sections	18127
@NP	the rubrospinal tract	18152
@NP	the dorsolateral funiculus	18177
@NP	This	18205
@NP	a measure of rubrospinal axon retraction	18221
@NP	a measure	18221
@NP	rubrospinal axon retraction	18234
@NP	the injury	18297
@NP	The efficacy of the axonal tracing	18309
@NP	The efficacy	18309
@NP	the axonal tracing	18325
@NP	the axonal	18325
@NP	the number	18370
@NP	rubrospinal axons measured on three different cervical coronal sections at C2	18384
@NP	rubrospinal axons	18384
@NP	three different cervical coronal sections	18414
@NP	C2	18459
@NP	Lesion area and cavity size	18463
@NP	Lesion area	18463
@NP	cavity size	18479
@NP	each animal	18511
@NP	the lesion area	18536
@NP	GFAP immunoreactivity	18563
@NP	three	18588
@NP	levels	18602
@NP	the dorsal root entry zone and the central canal	18637
@NP	the dorsal root entry zone	18637
@NP	the central canal	18668
@NP	the total pixels in this area	18703
@NP	the total pixels	18703
@NP	this area	18723
@NP	GFAP immunoreactivity	18734
@NP	the intensity	18783
@NP	a 50-µm width area	18804
@NP	the lesion site	18838
@NP	these former three longitudinal sections	18857
@NP	the analogous area	18916
@NP	the contralateral uninjured side of the spinal cord	18938
@NP	the contralateral uninjured side	18938
@NP	the spinal cord	18974
@NP	Immunopositive cellular or axonal density measurements	18991
@NP	axonal density	19018
@NP	Ramer	19064
@NP	et al. -LRB- 2004b -RRB-	19070
@NP	et al.	19070
@NP	2004b	19078
@NP	brief	19089
@NP	images	19096
@NP	three sections -LRB- per animal -RRB-	19122
@NP	three sections	19122
@NP	animal	19142
@NP	the horizontal plane	19153
@NP	the dorsal root entry zone and the central canal	19202
@NP	the dorsal root entry zone	19202
@NP	the central canal	19233
@NP	A Laplace transformation	19252
@NP	the edges of the immunoreactive axonal and cellular profiles	19305
@NP	the edges	19305
@NP	the immunoreactive axonal and cellular profiles	19318
@NP	This step	19367
@NP	fluctuations in the brightness of the immunofluorescent signal	19393
@NP	fluctuations	19393
@NP	the brightness of the immunofluorescent signal	19409
@NP	the brightness	19409
@NP	the immunofluorescent signal	19427
@NP	a threshold -LRB- using the same throughout the experiment -RRB-	19470
@NP	a threshold	19470
@NP	the same	19489
@NP	the experiment	19509
@NP	an overlay	19541
@NP	the axonal profiles	19593
@NP	The pixel area occupied by the thresholded axonal profiles	19614
@NP	The pixel area	19614
@NP	the thresholded axonal profiles	19641
@NP	the area -LRB- pixel number -RRB- of the selected measurement window	19688
@NP	the area -LRB- pixel number -RRB-	19688
@NP	the area	19688
@NP	pixel number	19698
@NP	the selected measurement window	19715
@NP	axonal density values -LRB- ratios -RRB-	19759
@NP	axonal density values	19759
@NP	ratios	19782
@NP	The same procedure	19791
@NP	the GFP-positive transplanted cells	19825
@NP	a measure	19871
@NP	their density	19884
@NP	the density of their cytoplasmic and nuclear borders	19917
@NP	the density	19917
@NP	their cytoplasmic and nuclear borders	19932
@NP	their cytoplasmic	19932
@NP	nuclear borders	19954
@NP	the measurement window	19978
@NP	Averaged axonal and cell density measurements from each treatment group	20002
@NP	Averaged axonal and cell density measurements	20002
@NP	each treatment group	20053
@NP	a function of the distance from the lesion epicenter	20104
@NP	a function	20104
@NP	the distance from the lesion epicenter	20118
@NP	the distance	20118
@NP	the lesion epicenter	20136
@NP	Statistical analysis	20158
@NP	A two-way repeated anova	20179
@NP	interactions between treatment and distance	20223
@NP	interactions	20223
@NP	treatment and distance	20244
@NP	the axonal and cellular density	20271
@NP	interactions between treatment and time course	20318
@NP	interactions	20318
@NP	treatment and time course	20339
@NP	the behavioral outcomes	20369
@NP	A one-way anova	20394
@NP	differences in the axonal or cellular density	20429
@NP	differences	20429
@NP	the axonal or cellular density	20444
@NP	each given distance	20478
@NP	differences in behavioral outcome measurements	20512
@NP	differences	20512
@NP	behavioral outcome measurements	20527
@NP	each time-point	20562
@NP	A one-way anova was used to detect differences between	20579
@NP	A one-way anova	20579
@NP	differences	20614
@NP	density measurements	20643
@NP	rubrospinal axon retraction and lesion area measurements	20675
@NP	the treatment	20745
@NP	The data	20760
@NP	further analysed using the post hoc Tukey -- Kramer test	20774
@NP	further	20774
@NP	the post hoc Tukey	20797
@NP	the post	20797
@NP	Kramer test	20816
@NP	the cases where the variables did not fit a normal distribution	20832
@NP	the cases	20832
@NP	the variables	20848
@NP	a normal distribution	20874
@NP	the non-parametric Kruskal -- Wallis	20897
@NP	the non-parametric Kruskal	20897
@NP	Wallis	20925
@NP	sum test	20939
@NP	a chi-square test	20970
@NP	all cases	20992
@NP	significance	21003
@NP	P	21029
@NP	Results Table 1 .	21040
@NP	Results	21040
@NP	Table 1	21048
@NP	Number of animals	21057
@NP	Number	21057
@NP	animals	21067
@NP	histological and behavioral quantifications Fig. 1	21084
@NP	histological and behavioral quantifications	21084
@NP	Fig. 1	21129
@NP	Experimental design .	21137
@NP	The dorsolateral funiculus including the rubrospinal tract	21158
@NP	The dorsolateral funiculus	21158
@NP	the rubrospinal tract	21195
@NP	C4 -- C5	21235
@NP	C4	21235
@NP	C5	21238
@NP	Olfactory ensheathing cells -LRB- OECs -RRB-	21242
@NP	Olfactory ensheathing cells	21242
@NP	OECs	21271
@NP	the lamina-propria -LRB- LP -RRB-	21290
@NP	neo-natal mouse	21317
@NP	GFP	21344
@NP	1 mm	21386
@NP	the lesion epicenter	21395
@NP	DMEM	21417
@NP	control	21438
@NP	the same locations	21451
@NP	combination with this spinal bridge	21474
@NP	combination	21474
@NP	this spinal bridge	21491
@NP	rubrospinal neurons	21511
@NP	brain-derived neurotrophic factor	21549
@NP	BDNF	21584
@NP	vehicle	21593
@NP	control	21605
@NP	2 weeks via a cannula inserted into the vicinity of the red nucleus	21618
@NP	2 weeks	21618
@NP	a cannula inserted into the vicinity of the red nucleus	21630
@NP	a cannula	21630
@NP	the vicinity of the red nucleus	21654
@NP	the vicinity	21654
@NP	the red nucleus	21670
@NP	Fig. 2 .	21688
@NP	Fig.	21688
@NP	2	21693
@NP	Olfactory ensheathing cells -LRB- OECs -RRB-	21696
@NP	Olfactory ensheathing cells	21696
@NP	OECs	21725
@NP	the injured spinal cord	21738
@NP	rubrospinal axons	21767
@NP	-LRB- A -RRB- Camera lucida of rubrospinal axons .	21804
@NP	-LRB- A -RRB-	21804
@NP	Camera lucida of rubrospinal axons	21808
@NP	Camera lucida	21808
@NP	rubrospinal axons	21825
@NP	Representative	21844
@NP	longitudinal spinal cord sections	21859
@NP	the dorsolateral funiculus level for different treatments and their combinations	21896
@NP	the dorsolateral funiculus level	21896
@NP	different treatments and their combinations	21933
@NP	different treatments	21933
@NP	their combinations	21958
@NP	rubrospinal axons	21983
@NP	the white matter	22011
@NP	the rostral OECs graft -LRB- light gray area -RRB-	22042
@NP	the rostral OECs graft	22042
@NP	light gray area	22066
@NP	the edge of the OEC	22096
@NP	the edge	22096
@NP	the OEC	22108
@NP	transplants bridging the lesion site	22116
@NP	transplants	22116
@NP	the lesion site	22137
@NP	Rubrospinal branching within the gray matter -LRB- dark gray area -RRB-	22154
@NP	Rubrospinal	22154
@NP	the gray matter -LRB- dark gray area -RRB-	22183
@NP	the gray matter	22183
@NP	dark gray area	22200
@NP	B and C	22237
@NP	B	22237
@NP	C	22243
@NP	Horizontal sections of the cervical spinal cord injury site	22246
@NP	Horizontal sections	22246
@NP	the cervical spinal cord injury site	22269
@NP	astrocytes -LSB- glial fibrillary acidic protein -LRB- GFAP -RRB-	22324
@NP	astrocytes -LSB- glial fibrillary acidic protein	22324
@NP	astrocytes -LSB-	22324
@NP	GFAP	22369
@NP	blue -RSB-	22378
@NP	LP-OECs -LSB- green fluorescent protein -LRB- GFP -RRB-	22385
@NP	LP-OECs -LSB- green fluorescent protein	22385
@NP	GFP	22421
@NP	green -RSB- and rubrospinal axons	22429
@NP	biotinylated dextran amine -LRB- BDA -RRB- in red -RSB-	22459
@NP	biotinylated dextran amine	22459
@NP	BDA	22487
@NP	red -RSB-	22495
@NP	-LRB- B -RRB- Vehicle	22501
@NP	-LRB- B -RRB-	22501
@NP	Vehicle	22505
@NP	OEC-treated rats	22514
@NP	vehicle	22547
@NP	the rubrospinal neuron level and OECs	22558
@NP	the rubrospinal neuron level	22558
@NP	OECs	22591
@NP	the spinal cord level	22599
@NP	-LRB- C -RRB- Brain-derived neurotrophic factor -LRB- BDNF -RRB-	22622
@NP	-LRB- C -RRB-	22622
@NP	Brain-derived neurotrophic factor -LRB- BDNF -RRB-	22626
@NP	Brain-derived neurotrophic factor	22626
@NP	BDNF	22661
@NP	OECtreated rats	22667
@NP	Neither treatment alone or in combination	22684
@NP	Neither treatment	22684
@NP	combination	22714
@NP	regeneration of rubrospinal axons	22735
@NP	regeneration	22735
@NP	rubrospinal axons	22751
@NP	The white asterisks in B and C	22770
@NP	The white asterisks	22770
@NP	B and C	22793
@NP	the lesion epicenters	22810
@NP	Fig. 3 .	22834
@NP	Fig.	22834
@NP	3	22839
@NP	LP-olfactory ensheathing cells -LRB- OECs -RRB-	22842
@NP	LP-olfactory ensheathing cells	22842
@NP	OECs	22874
@NP	the cell body treatment	22896
@NP	lesion area , cavity formation and glial scar formation	22930
@NP	lesion area	22930
@NP	cavity formation	22943
@NP	glial scar formation	22964
@NP	-LRB- A -RRB- Mean lesion area -LRB- GFAP-negative area -RRB- .	22986
@NP	-LRB- A -RRB-	22986
@NP	Mean lesion area -LRB- GFAP-negative area -RRB-	22990
@NP	Mean lesion area	22990
@NP	GFAP-negative area	23008
@NP	-LRB- B -RRB-	23029
@NP	Mean cavitation area -LRB- background area within the lesion site -RRB-	23033
@NP	Mean cavitation area	23033
@NP	background area within the lesion site	23055
@NP	background area	23055
@NP	the lesion site	23078
@NP	-LRB- C -RRB- Percentage of lesion site	23096
@NP	-LRB- C -RRB-	23096
@NP	lesion site	23114
@NP	cavity formation	23138
@NP	-LRB- D -RRB- GFAP immunodensity along the lesion site	23156
@NP	-LRB- D -RRB- GFAP immunodensity	23156
@NP	-LRB- D -RRB-	23156
@NP	GFAP immunodensity	23160
@NP	the lesion site	23185
@NP	the contralateral non-injured side	23215
@NP	Error bars	23251
@NP	SEM -LSB- Kruskal -- Wallis , P < 0.01 : *	23271
@NP	SEM -LSB- Kruskal -- Wallis , P < 0.01 :	23271
@NP	SEM	23271
@NP	Kruskal -- Wallis , P < 0.01 :	23276
@NP	Kruskal	23276
@NP	Wallis , P < 0.01	23284
@NP	Wallis	23284
@NP	P < 0.01	23292
@NP	P <	23292
@NP	P	23292
@NP	0.01	23296
@NP	Veh -- DMEM	23317
@NP	Veh	23317
@NP	DMEM	23321
@NP	brain-derived neurotrophic factor -LRB- BDNF -RRB- -- DMEM and Veh -- DMEM -RSB-	23343
@NP	brain-derived neurotrophic factor -LRB- BDNF -RRB-	23343
@NP	brain-derived neurotrophic factor	23343
@NP	BDNF	23378
@NP	DMEM and Veh -- DMEM	23384
@NP	DMEM and Veh	23384
@NP	DMEM	23397
@NP	Fig. 4 .	23405
@NP	Fig.	23405
@NP	4	23410
@NP	LP-olfactory ensheathing cells	23413
@NP	OECs	23445
@NP	survival	23451
@NP	the cell body treatment	23479
@NP	OEC density	23504
@NP	a function	23519
@NP	the distance	23533
@NP	the lesion epicenter from brain-derived neurotrophic factor -LRB- BDNF -RRB-	23551
@NP	the lesion epicenter	23551
@NP	brain-derived neurotrophic factor -LRB- BDNF -RRB-	23577
@NP	brain-derived neurotrophic factor	23577
@NP	BDNF	23612
@NP	OECs - and Veh -- OECs-treated rats	23618
@NP	OECs	23618
@NP	Veh	23628
@NP	OECs-treated rats	23633
@NP	Error bars	23652
@NP	SEM	23672
@NP	two-way repeated-measures	23677
@NP	anova	23703
@NP	no treatment · distance interaction	23718
@NP	P = 0.985	23755
@NP	P	23755
@NP	0.985	23759
@NP	a treatment effect , P = 0.959	23769
@NP	a treatment effect	23769
@NP	P = 0.959	23789
@NP	P	23789
@NP	0.959	23793
@NP	GFP , green fluorescent protein .	23801
@NP	GFP	23801
@NP	green fluorescent protein	23806
@NP	Fig. 5 .	23834
@NP	Fig.	23834
@NP	5	23839
@NP	three treatments , olfactory ensheathing cell -LRB- OEC -RRB- transplantation ,	23846
@NP	three treatments	23846
@NP	olfactory ensheathing cell -LRB- OEC -RRB- transplantation	23864
@NP	olfactory ensheathing cell	23864
@NP	OEC	23892
@NP	transplantation	23897
@NP	brain-derived neurotrophic factor -LRB- BDNF -RRB-	23939
@NP	brain-derived neurotrophic factor	23939
@NP	BDNF	23974
@NP	their combination	23991
@NP	retraction of rubrospinal axons	24019
@NP	retraction	24019
@NP	rubrospinal axons	24033
@NP	lesion epicenter	24056
@NP	-LRB- A -RRB-	24074
@NP	Distance	24078
@NP	rubrospinal axonal terminals	24090
@NP	the lesion epicenter as a function of different treatments	24124
@NP	the lesion epicenter	24124
@NP	a function of different treatments	24148
@NP	a function	24148
@NP	different treatments	24162
@NP	-LRB- B -RRB-	24184
@NP	Number of rubrospinal axons at the cervical segment C2 rostral to the lesion	24188
@NP	Number	24188
@NP	rubrospinal axons at the cervical segment C2 rostral to the lesion	24198
@NP	rubrospinal axons	24198
@NP	the cervical segment C2 rostral to the lesion	24219
@NP	the cervical segment C2 rostral	24219
@NP	the lesion	24254
@NP	Error bars	24266
@NP	SEM	24286
@NP	oneway anova , P <	24293
@NP	oneway anova , P	24293
@NP	<	24309
@NP	0.05	24311
@NP	the control group Veh	24331
@NP	DMEM	24353
@NP	the combinatorial therapy BDNF -- OECs	24379
@NP	the combinatorial therapy BDNF	24379
@NP	OECs	24410
@NP	regeneration	24431
@NP	it	24445
@NP	the number of axons	24458
@NP	the number	24458
@NP	axons	24472
@NP	C2	24481
@NP	the retraction of rubrospinal terminals	24498
@NP	the retraction	24498
@NP	rubrospinal terminals	24516
@NP	the lesion epicenter	24543
@NP	Fig. 6 .	24566
@NP	Fig.	24566
@NP	6	24571
@NP	Olfactory ensheathing cells -LRB- OECs -RRB-	24574
@NP	Olfactory ensheathing cells	24574
@NP	OECs	24603
@NP	regeneration of unidentified thin and thick axons	24618
@NP	regeneration	24618
@NP	unidentified thin and thick axons	24634
@NP	the cell body treatment	24684
@NP	Axonal density of thin and thick axons	24709
@NP	Axonal density	24709
@NP	thin and thick axons	24727
@NP	neurofilament -LRB- NF -RRB-	24749
@NP	neurofilament	24749
@NP	NF	24764
@NP	beta-III-tubulin -LRB- tub -RRB- - positive structures , respectively -RSB-	24777
@NP	beta-III-tubulin	24777
@NP	tub	24795
@NP	positive structures , respectively	24800
@NP	positive structures	24800
@NP	the OECs graft	24846
@NP	the cell body treatment	24874
@NP	BDNF -- OEC treatment	24918
@NP	BDNF	24918
@NP	OEC treatment	24923
@NP	the axonal density	24947
@NP	no significant differences	24976
@NP	both groups -LRB- anova , P = 0.437 -RRB-	25025
@NP	both groups	25025
@NP	anova , P = 0.437	25038
@NP	anova	25038
@NP	P = 0.437	25045
@NP	P	25045
@NP	0.437	25049
@NP	Error bars	25057
@NP	SEM	25077
@NP	Fig. 7 .	25083
@NP	Fig.	25083
@NP	7	25088
@NP	Absence	25091
@NP	regenerative sprouting of supraspinal axons and peripheral afferents into	25102
@NP	regenerative	25102
@NP	supraspinal axons and peripheral afferents	25128
@NP	supraspinal axons	25128
@NP	peripheral afferents	25150
@NP	LP-olfactory ensheathing cells -LRB- OECs -RRB-	25186
@NP	LP-olfactory ensheathing cells	25186
@NP	OECs	25218
@NP	small diameter peptidergic fibers	25232
@NP	OECs	25267
@NP	alone -LRB- left column -RRB-	25272
@NP	alone	25272
@NP	column	25284
@NP	combination with brain-derived neurotrophic factor	25298
@NP	combination	25298
@NP	brain-derived neurotrophic factor	25315
@NP	BDNF ; middle column -RRB-	25350
@NP	BDNF	25350
@NP	middle column	25356
@NP	immunoreactivity of marker of serotoninergic re-uptake vesicles -LRB- SERT - ;	25381
@NP	immunoreactivity	25381
@NP	marker	25401
@NP	serotoninergic re-uptake vesicles -LRB- SERT -	25411
@NP	serotoninergic re-uptake vesicles	25411
@NP	SERT	25446
@NP	A -- C	25453
@NP	C	25455
@NP	tyrosine hydroxylase	25462
@NP	TH	25484
@NP	; D -- F ; marker	25487
@NP	D -- F	25489
@NP	D	25489
@NP	F	25491
@NP	noradrenergic fibers	25504
@NP	positive fibers rostral	25526
@NP	the lesion site , but	25553
@NP	the lesion site	25553
@NP	poor or no regeneration of these fibers	25583
@NP	poor or no regeneration	25583
@NP	these fibers	25610
@NP	the OECs graft	25628
@NP	OECs	25655
@NP	immunoreactivity	25670
@NP	substance-P	25690
@NP	Sub-P	25703
@NP	fibers -LRB- G -- I ; marker of peripheral afferent terminals -RRB-	25719
@NP	fibers	25719
@NP	G	25727
@NP	I ; marker of peripheral afferent terminals	25729
@NP	I	25729
@NP	marker of peripheral afferent terminals	25732
@NP	marker	25732
@NP	peripheral afferent terminals	25742
@NP	the lesion site	25783
@NP	the OECs graft	25821
@NP	Only calcitonin gene-related peptide -LRB- CGRP -RRB-	25837
@NP	Only calcitonin	25837
@NP	gene-related peptide -LRB- CGRP -RRB-	25853
@NP	gene-related peptide	25853
@NP	CGRP	25875
@NP	positive fibers	25881
@NP	J	25898
@NP	L ; marker of peptidergic small diameter peripheral afferent terminals	25900
@NP	L	25900
@NP	marker of peptidergic small diameter peripheral afferent terminals	25903
@NP	marker	25903
@NP	peptidergic small diameter peripheral afferent terminals	25913
@NP	the engrafted OECs	25981
@NP	the	25981
@NP	OECs	25995
@NP	Right column	26001
@NP	axonal density of SERT - , TH - , Sub-P	26015
@NP	axonal density of SERT - , TH -	26015
@NP	axonal density	26015
@NP	SERT	26033
@NP	TH	26040
@NP	Sub-P	26045
@NP	CGRP-positive fibers	26056
@NP	a function of the distance from the lesion epicenter according to the treatment	26080
@NP	a function	26080
@NP	the distance from the lesion epicenter according to the treatment	26094
@NP	the distance	26094
@NP	the lesion epicenter according to the treatment	26112
@NP	the lesion epicenter	26112
@NP	the treatment	26146
@NP	significant increases in CGRP axonal density in BDNF -- OEC - and Veh --	26166
@NP	significant increases	26166
@NP	CGRP axonal density in BDNF -- OEC - and Veh --	26191
@NP	CGRP axonal density in BDNF -- OEC	26191
@NP	CGRP axonal density	26191
@NP	BDNF	26214
@NP	Veh	26228
@NP	rats	26245
@NP	comparison with BDNF -- DMEM -	26253
@NP	comparison	26253
@NP	BDNF -- DMEM -	26269
@NP	BDNF	26269
@NP	DMEM	26274
@NP	light gray line	26288
@NP	Veh -- DMEM - treated ones	26309
@NP	Veh	26309
@NP	DMEM	26314
@NP	treated ones	26320
@NP	Error bars	26334
@NP	SEM	26354
@NP	Two-way repeated-measures anova -LRB- P < 0.05 -RRB-	26359
@NP	Two-way repeated-measures anova	26359
@NP	P < 0.05	26392
@NP	P	26392
@NP	< 0.05	26394
@NP	<	26394
@NP	0.05	26396
@NP	a time · distance interaction	26411
@NP	SERT , TH and CGRP fibers	26445
@NP	SERT	26445
@NP	TH	26451
@NP	CGRP fibers	26458
@NP	One-way anova	26471
@NP	P	26486
@NP	<	26488
@NP	0.05	26490
@NP	-LRB- BDNF -- OECs and Veh -- OECs -RRB-	26497
@NP	BDNF	26498
@NP	OECs and Veh -- OECs	26503
@NP	OECs	26503
@NP	Veh -- OECs	26512
@NP	Veh	26512
@NP	OECs	26516
@NP	Veh	26537
@NP	DMEM and BDNF -- DMEM	26541
@NP	DMEM and BDNF	26541
@NP	DMEM	26555
@NP	BDNF	26564
@NP	OECs	26569
@NP	three other groups	26588
@NP	Fig. 8 .	26609
@NP	Fig.	26609
@NP	8	26614
@NP	Combinatorial therapy	26617
@NP	functional recovery	26662
@NP	-LRB- A -RRB-	26683
@NP	Time course of percentage changes of use of left and both forelimbs	26687
@NP	Time course	26687
@NP	percentage changes of use of left and both forelimbs	26702
@NP	percentage changes	26702
@NP	use of left and both forelimbs	26724
@NP	use	26724
@NP	left and both forelimbs	26731
@NP	left	26731
@NP	both forelimbs	26740
@NP	the wall for the cylinder	26766
@NP	the wall	26766
@NP	the cylinder	26779
@NP	spinal cord injury and treatment	26814
@NP	-LRB- B -RRB-	26848
@NP	Time course	26852
@NP	changes	26867
@NP	the motor performance for reaching , grasping and retrieving a food pellet	26878
@NP	the motor performance	26878
@NP	a food pellet	26938
@NP	Time course	26957
@NP	changes	26972
@NP	mechanical thresholds	26983
@NP	left and right forepaws	27008
@NP	Time course	27037
@NP	changes	27052
@NP	thermal thresholds	27063
@NP	left and right forepaws	27085
@NP	the left forepaw	27114
@NP	two-way repeated-measures anova -LRB- P < 0.05 -RRB-	27132
@NP	two-way repeated-measures anova	27132
@NP	P < 0.05	27165
@NP	P	27165
@NP	< 0.05	27167
@NP	<	27167
@NP	0.05	27169
@NP	a time and treatment effect	27184
@NP	the cylinder test	27216
@NP	task	27260
@NP	the left forelimb	27273
@NP	both sensory tests	27295
@NP	one-way repeated anova , P	27315
@NP	one-way repeated anova	27315
@NP	P	27339
@NP	< 0.05 : * brain-derived neurotrophic factor -LRB- BDNF -RRB-	27341
@NP	<	27341
@NP	0.05 : * brain-derived neurotrophic factor -LRB- BDNF -RRB-	27343
@NP	0.05 : * brain-derived neurotrophic factor	27343
@NP	0.05	27343
@NP	brain-derived neurotrophic factor	27350
@NP	BDNF	27385
@NP	olfactory ensheathing cells -LRB- OECs -RRB- compared with control group Veh	27391
@NP	olfactory ensheathing cells -LRB- OECs -RRB-	27391
@NP	olfactory ensheathing cells	27391
@NP	OECs	27420
@NP	control group Veh	27440
@NP	BDNF	27466
@NP	OECs compared with all groups	27471
@NP	OECs	27471
@NP	all groups	27490
@NP	*** BDNF -- OECs compared with -LRB- Veh -- DMEM and Veh -- OECs -RRB-	27502
@NP	*** BDNF	27502
@NP	OECs compared with -LRB- Veh -- DMEM and Veh -- OECs -RRB-	27510
@NP	OECs	27510
@NP	Veh	27530
@NP	DMEM and Veh -- OECs	27534
@NP	DMEM and Veh	27534
@NP	OECs	27547
@NP	+ BDNF -- DMEM	27558
@NP	BDNF -- DMEM	27559
@NP	BDNF	27559
@NP	DMEM	27564
@NP	Veh -- DMEM and Veh -- OECs	27584
@NP	Veh	27584
@NP	DMEM and Veh -- OECs	27588
@NP	DMEM and Veh	27588
@NP	OECs	27601
@NP	Fig. 9 .	27609
@NP	Fig.	27609
@NP	9	27614
@NP	Poor motor performances	27617
@NP	hypersensitivity	27676
@NP	brain-derived neurotrophic factor -LRB- BDNF -RRB-	27696
@NP	brain-derived neurotrophic factor	27696
@NP	BDNF	27731
@NP	olfactory ensheathing cells -LRB- OECs -RRB-	27737
@NP	olfactory ensheathing cells	27737
@NP	OECs	27766
@NP	rats	27780
@NP	Correlation	27786
@NP	motor performances	27806
@NP	the cylinder test -LRB- A -RRB-	27829
@NP	the cylinder test	27829
@NP	A	27848
@NP	the food-pellet	27854
@NP	task -LRB- B -RRB- and thermal thresholds in individual BDNF	27879
@NP	task	27879
@NP	B	27885
@NP	thermal thresholds in individual BDNF	27892
@NP	thermal thresholds	27892
@NP	individual BDNF	27914
@NP	OECs	27930
@NP	Veh -- OECs - and BDNF -- DMEM -	27937
@NP	Veh	27937
@NP	OECs - and BDNF -- DMEM	27941
@NP	OECs	27941
@NP	BDNF	27951
@NP	DMEM	27956
@NP	rats	27970
@NP	Significant correlation coefficients only for BDNF	27976
@NP	Significant correlation coefficients	27976
@NP	BDNF	28022
@NP	OEC-treated rats -LRB- included in graphs -RRB-	28027
@NP	OEC-treated rats	28027
@NP	graphs	28057
@NP	We	28067
@NP	some rubrospinal axon growth	28090
@NP	LP-OEC grafts implanted into the lesion site , but no regeneration beyond	28124
@NP	LP-OEC grafts	28124
@NP	the lesion site	28153
@NP	no regeneration	28174
@NP	Ramer	28198
@NP	et al. , 2004a	28204
@NP	et al.	28204
@NP	2004a	28212
@NP	we	28226
@NP	highly enriched LP-OECs	28250
@NP	we	28305
@NP	this	28328
@NP	cavity formation , GFAP expression at the lesion boundary	28341
@NP	cavity formation	28341
@NP	GFAP expression at the lesion boundary	28359
@NP	GFAP expression	28359
@NP	the lesion boundary	28378
@NP	the growth of NF-positive axons	28411
@NP	the growth	28411
@NP	NF-positive axons	28425
@NP	the lesion site -LRB- Richter et al. , 2005 -RRB-	28448
@NP	the lesion site	28448
@NP	Richter	28465
@NP	et al. , 2005	28473
@NP	et al.	28473
@NP	2005	28481
@NP	the present study	28491
@NP	we	28509
@NP	this improved transplantation approach	28521
@NP	a 2-week infusion of BDNF	28565
@NP	a 2-week infusion	28565
@NP	BDNF	28586
@NP	the vicinity of the cell bodies of the rubrospinal neurons	28596
@NP	the vicinity	28596
@NP	the cell bodies of the rubrospinal neurons	28612
@NP	the cell bodies	28612
@NP	the rubrospinal neurons	28631
@NP	their regenerative propensity as well as functional recovery	28675
@NP	their regenerative propensity	28675
@NP	functional recovery	28716
@NP	Fig. 1 and Table 1 for experimental design	28741
@NP	Fig. 1	28741
@NP	Table 1 for experimental design	28752
@NP	Table 1	28752
@NP	experimental design	28764
@NP	OECs	28786
@NP	the lesion	28796
@NP	cavity and glial scar formation	28819
@NP	Injury of the rat dorsolateral funiculus	28851
@NP	Injury	28851
@NP	the rat dorsolateral funiculus	28861
@NP	the formation of a lesion	28913
@NP	the formation	28913
@NP	a lesion	28930
@NP	cavitation	28944
@NP	a margin of hypertrophic , GFAP-positive astrocytes	28977
@NP	a margin	28977
@NP	hypertrophic , GFAP-positive astrocytes	28989
@NP	We	29029
@NP	this GFAPnegative area	29040
@NP	the epicenter	29066
@NP	` lesion area '	29083
@NP	the experimental groups	29107
@NP	transplanted cells	29150
@NP	cells invading from the roots and meninges	29180
@NP	cells	29180
@NP	the roots and meninges	29200
@NP	All three treatment groups	29224
@NP	Vehicle	29252
@NP	OEC , BDNF -- DMEM , BDNF -- OEC	29260
@NP	OEC	29260
@NP	BDNF -- DMEM , BDNF -- OEC	29265
@NP	BDNF	29265
@NP	DMEM , BDNF	29270
@NP	OEC	29281
@NP	smaller lesion areas	29303
@NP	our control group -LRB- Vehicle -- DMEM ; Fig. 2A -RRB-	29329
@NP	our control group	29329
@NP	Vehicle	29348
@NP	DMEM ; Fig. 2A	29356
@NP	DMEM	29356
@NP	Fig. 2A	29362
@NP	these measurements	29376
@NP	significance	29411
@NP	P = 0.14 BDNF	29425
@NP	P =	29425
@NP	0.14 BDNF	29429
@NP	OEC group ; Fig 3A	29439
@NP	OEC group	29439
@NP	Fig 3A	29450
@NP	Transplantation of OECs alone -LRB- Vehicle -- OEC -RRB-	29459
@NP	Transplantation	29459
@NP	OECs alone -LRB- Vehicle -- OEC -RRB-	29478
@NP	OECs alone	29478
@NP	OECs	29478
@NP	Vehicle -- OEC	29490
@NP	Vehicle	29490
@NP	OEC	29498
@NP	combination with BDNF treatment of the rubrospinal cell	29509
@NP	combination	29509
@NP	BDNF treatment of the rubrospinal cell	29526
@NP	BDNF treatment	29526
@NP	the rubrospinal cell	29544
@NP	BDNF -- OEC	29573
@NP	BDNF	29573
@NP	OEC	29578
@NP	the size	29594
@NP	the cavity area -LRB- Figs 2 and 3B -RRB-	29606
@NP	the cavity area	29606
@NP	Figs 2 and 3B	29623
@NP	Figs 2	29623
@NP	3B	29634
@NP	a decreased percentage of lesion area occupied by cavitation -LRB- Fig. 3C -RRB-	29667
@NP	a decreased percentage	29667
@NP	lesion area occupied by cavitation -LRB- Fig. 3C -RRB-	29693
@NP	lesion area	29693
@NP	cavitation -LRB- Fig. 3C -RRB-	29717
@NP	cavitation	29717
@NP	Fig. 3C	29729
@NP	Both groups	29739
@NP	OECs -LRB- Vehicle -- OEC and BDNF -- OEC ; Fig. 2B and C -RRB-	29761
@NP	OECs	29761
@NP	Vehicle	29767
@NP	OEC and BDNF -- OEC ; Fig. 2B and C	29775
@NP	OEC and BDNF	29775
@NP	OEC ; Fig. 2B and C	29788
@NP	OEC	29788
@NP	Fig. 2B and C	29793
@NP	reduced immunoreactivity	29815
@NP	GFAP	29844
@NP	less hypertrophy of reactive astrocytes -LRB- Fig. 3D -RRB-	29864
@NP	less hypertrophy	29864
@NP	reactive astrocytes -LRB- Fig. 3D -RRB-	29884
@NP	reactive astrocytes	29884
@NP	Fig. 3D	29905
@NP	the control group	29928
@NP	Cell body treatment with BDNF combined with DMEM at the spinal cord	29947
@NP	Cell body treatment	29947
@NP	BDNF combined with DMEM at the spinal cord	29972
@NP	BDNF	29972
@NP	DMEM	29991
@NP	the spinal cord	29999
@NP	a trend	30027
@NP	smaller cavity areas and GFAP immunoreactivity	30043
@NP	smaller cavity areas	30043
@NP	GFAP immunoreactivity	30068
@NP	these parameters	30100
@NP	significance	30133
@NP	the control group	30165
@NP	Fig. 3B -- D	30184
@NP	Fig. 3B	30184
@NP	D	30192
@NP	OEC survival	30206
@NP	cell body treatment	30239
@NP	BDNF -LRB- Fig. 4 , two-way repeated anova ,	30264
@NP	BDNF	30264
@NP	Fig. 4 , two-way repeated anova	30270
@NP	Fig. 4	30270
@NP	two-way repeated anova	30278
@NP	P	30302
@NP	0.95 for the treatment · distance interaction	30306
@NP	0.95	30306
@NP	the treatment · distance interaction	30315
@NP	summary , the minimal neuroprotection	30357
@NP	summary	30357
@NP	the minimal neuroprotection	30366
@NP	lesion area measurement	30407
@NP	the combination of OECs with BDNF	30444
@NP	the combination	30444
@NP	OECs with BDNF	30463
@NP	OECs	30463
@NP	BDNF	30473
@NP	OEC or BDNF treatment	30501
@NP	alone , i.e. the effects were not additive	30523
@NP	alone	30523
@NP	i.e. the effects were not additive	30530
@NP	i.e.	30530
@NP	the effects	30535
@NP	the combination of OECs and BDNF	30577
@NP	the combination	30577
@NP	OECs and BDNF	30596
@NP	an additive effect	30623
@NP	astrocytic hypertrophy	30645
@NP	cavity formation and percentage of the lesion area occupied by cavitation	30669
@NP	cavity formation and percentage	30669
@NP	the lesion area	30704
@NP	cavitation	30732
@NP	transplantation of OECs	30750
@NP	transplantation	30750
@NP	OECs	30769
@NP	the observed beneficial effects on GFAP immunoreactivity and cavity formation	30804
@NP	the observed beneficial effects	30804
@NP	GFAP immunoreactivity and cavity formation	30839
@NP	GFAP immunoreactivity	30839
@NP	cavity formation	30865
@NP	Prevention	30883
@NP	rubrospinal axon retraction	30897
@NP	We	30925
@NP	the regeneration of rubrospinal axons	30942
@NP	the regeneration	30942
@NP	rubrospinal axons	30962
@NP	them	30992
@NP	the anterogradely	31002
@NP	tracer BDA	31032
@NP	rubrospinal axons	31054
@NP	axotomy -LRB- Ye & Houle , 1997 ; Jin et al. , 2002 -RRB-	31086
@NP	axotomy	31086
@NP	Ye	31095
@NP	& Houle , 1997 ; Jin et al. , 2002	31098
@NP	Houle , 1997 ; Jin et al.	31100
@NP	Houle , 1997	31100
@NP	Houle	31100
@NP	1997	31107
@NP	Jin et al.	31113
@NP	Jin	31113
@NP	et al.	31117
@NP	2002	31125
@NP	our control condition -LRB- Veh -- DMEM ; Fig. 2A -RRB-	31139
@NP	our control condition	31139
@NP	Veh	31162
@NP	DMEM ; Fig. 2A	31166
@NP	DMEM	31166
@NP	Fig. 2A	31172
@NP	rostral ⁄ caudal DMEM injections	31191
@NP	caudal DMEM injections	31201
@NP	most rubrospinal axons	31225
@NP	1700 µm -LRB- ± 323 µm -RRB-	31260
@NP	1700 µm	31260
@NP	± 323 µm	31269
@NP	±	31269
@NP	323 µm	31271
@NP	rostral to the lesion center	31279
@NP	rostral	31279
@NP	the lesion center	31290
@NP	contrast	31312
@NP	all three experimental conditions	31325
@NP	BDNF -- DMEM , Veh -- OECs and their combination BDNF -- OEC	31360
@NP	BDNF	31360
@NP	DMEM , Veh -- OECs and their combination BDNF -- OEC	31365
@NP	DMEM	31365
@NP	Veh -- OECs and their combination BDNF -- OEC	31371
@NP	Veh	31371
@NP	OECs and their combination BDNF	31376
@NP	OECs	31376
@NP	their combination BDNF	31385
@NP	OEC	31408
@NP	the bulk of these rubrospinal axons	31414
@NP	the bulk	31414
@NP	these rubrospinal axons	31426
@NP	500 µm	31468
@NP	the epicenter -LRB- P < 0.01 ; Figs 2A and 5A -RRB-	31488
@NP	the epicenter	31488
@NP	P < 0.01 ; Figs 2A and 5A	31503
@NP	P	31503
@NP	< 0.01 ; Figs 2A and 5A	31505
@NP	< 0.01	31505
@NP	<	31505
@NP	0.01	31507
@NP	Figs 2A and 5A	31513
@NP	Figs 2A	31513
@NP	5A	31525
@NP	we	31536
@NP	atrophic retracting axons	31566
@NP	axons	31613
@NP	it	31620
@NP	most anterogradely traced axons	31649
@NP	most	31649
@NP	axons	31675
@NP	the host tissue	31694
@NP	the proximity of transplanted cells	31739
@NP	the proximity	31739
@NP	transplanted cells	31756
@NP	The straight course of many of these axons	31776
@NP	The straight course	31776
@NP	many of these axons	31799
@NP	many	31799
@NP	these axons	31807
@NP	the interpretation	31826
@NP	these	31850
@NP	these differences in rubrospinal axon profiles at the rostral lesion edge	31890
@NP	these differences	31890
@NP	rubrospinal axon profiles at the rostral lesion edge	31911
@NP	rubrospinal axon profiles	31911
@NP	the rostral lesion edge	31940
@NP	differences in the efficacy of anterograde tracing	31980
@NP	differences	31980
@NP	the efficacy of anterograde tracing	31995
@NP	the efficacy	31995
@NP	anterograde tracing	32011
@NP	anterograde	32011
@NP	The number	32032
@NP	rubrospinal axons	32046
@NP	BDA counted on coronal -LRB- i.e. cross -	32076
@NP	BDA	32076
@NP	on coronal -LRB- i.e. cross -	32088
@NP	on	32088
@NP	coronal -LRB- i.e. cross -	32091
@NP	coronal	32091
@NP	i.e. cross	32100
@NP	i.e.	32100
@NP	cross	32105
@NP	sections taken at C2	32113
@NP	sections	32113
@NP	C2	32131
@NP	the control group	32147
@NP	this	32170
@NP	significance -LRB- P = 0.11 ; Fig. 5B -RRB-	32189
@NP	significance	32189
@NP	P	32203
@NP	= 0.11 ; Fig. 5B	32205
@NP	= 0.11	32205
@NP	Fig. 5B	32213
@NP	the three treatment groups and the Vehicle	32230
@NP	the three treatment groups	32230
@NP	the Vehicle	32261
@NP	DMEM-treated control group	32273
@NP	all three treatments	32308
@NP	BDNF	32335
@NP	DMEM , Veh -- OEC or their combination -RRB-	32340
@NP	DMEM	32340
@NP	Veh -- OEC or their combination -RRB-	32346
@NP	Veh	32346
@NP	OEC or their combination	32350
@NP	OEC	32350
@NP	their combination	32357
@NP	the retraction of rubrospinal axons	32396
@NP	the retraction	32396
@NP	rubrospinal axons	32414
@NP	the lesion epicenter -LRB- P < 0.01 ; Fig. 5A -RRB-	32437
@NP	the lesion epicenter	32437
@NP	P < 0.01 ; Fig. 5A	32459
@NP	P	32459
@NP	< 0.01 ; Fig. 5A	32461
@NP	< 0.01	32461
@NP	<	32461
@NP	0.01	32463
@NP	Fig. 5A	32469
@NP	Fig.	32469
@NP	5A	32474
@NP	neither treatment condition	32483
@NP	regeneration of rubrospinal axons	32520
@NP	regeneration	32520
@NP	rubrospinal axons	32536
@NP	the transplanted LP-OECs	32573
@NP	these limited effects on rubrospinal regeneration	32607
@NP	these limited effects	32607
@NP	rubrospinal regeneration	32632
@NP	OECs	32658
@NP	various axonal populations -LRB- NF-200 and ⁄ or tub-positive structures -RRB-	32685
@NP	various axonal populations	32685
@NP	NF-200 and ⁄ or tub-positive structures	32713
@NP	NF-200 and ⁄	32713
@NP	tub-positive structures	32729
@NP	the OEC-filled lesion site	32759
@NP	the cell body treatment -LRB- Fig. 6 ; one-way anova , P = 0.43 -RRB-	32802
@NP	the cell body treatment	32802
@NP	Fig. 6 ; one-way anova , P = 0.43	32827
@NP	Fig. 6	32827
@NP	one-way anova , P = 0.43	32835
@NP	one-way anova	32835
@NP	P = 0.43	32850
@NP	P	32850
@NP	0.43	32854
@NP	We	32861
@NP	the sprouting of identified supra-spinal axons and peripheral afferents	32883
@NP	the sprouting	32883
@NP	identified supra-spinal axons and peripheral afferents	32900
@NP	identified supra-spinal axons	32900
@NP	peripheral afferents	32934
@NP	The immunoreactivity	32956
@NP	supra-spinal fibers	32981
@NP	SERT-positive fibers ; Fig. 7A -- C	33024
@NP	SERT-positive fibers	33024
@NP	Fig. 7A -- C	33046
@NP	Fig. 7A	33046
@NP	C	33054
@NP	TH-positive fibers ; Fig. 7D -- F	33076
@NP	TH-positive fibers	33076
@NP	Fig. 7D -- F	33096
@NP	Fig. 7D	33096
@NP	F	33104
@NP	the rostral lesion transplant interface	33128
@NP	caudal to the transplant in all groups	33173
@NP	the transplant in all	33183
@NP	the transplant	33183
@NP	all	33201
@NP	only a few axons	33222
@NP	the engrafted OECs	33249
@NP	the	33249
@NP	OECs	33263
@NP	Axonal density measurements	33269
@NP	significantly more SERT - and TH-positive fibers rostral	33306
@NP	significantly more SERT	33306
@NP	TH-positive fibers rostral	33335
@NP	the lesion	33365
@NP	OEC	33379
@NP	spinal cords -LRB- Veh -- OEC and BDNF -- OEC -RRB-	33391
@NP	spinal cords	33391
@NP	Veh	33405
@NP	OEC and BDNF -- OEC	33409
@NP	OEC and BDNF	33409
@NP	OEC	33422
@NP	controls	33441
@NP	The density of peripheral afferents positive for substance-P -LRB- Sub-P -RRB-	33451
@NP	The density	33451
@NP	peripheral afferents positive for substance-P -LRB- Sub-P -RRB-	33466
@NP	peripheral afferents positive for substance-P	33466
@NP	peripheral afferents	33466
@NP	substance-P	33500
@NP	Sub-P	33513
@NP	higher caudal	33524
@NP	the lesion site	33541
@NP	this phenomenon	33562
@NP	the groups -LRB- Fig. 7G -- I -RRB-	33616
@NP	the groups	33616
@NP	Fig. 7G -- I	33628
@NP	Fig. 7G	33628
@NP	I	33636
@NP	contrast	33643
@NP	small-diameter peptidergic nociceptive fibers containing CGRP	33653
@NP	small-diameter peptidergic nociceptive fibers	33653
@NP	CGRP	33710
@NP	the OEC transplanted rats , both at the cranial and caudal lesion margins	33743
@NP	the OEC transplanted rats	33743
@NP	both at the cranial and caudal lesion margins	33770
@NP	both	33770
@NP	the cranial and caudal lesion margins	33778
@NP	the epicenters of the transplants -LRB- Fig. 7J -- L -RRB-	33834
@NP	the epicenters	33834
@NP	the transplants -LRB- Fig. 7J -- L -RRB-	33852
@NP	the transplants	33852
@NP	Fig. 7J -- L	33869
@NP	Fig. 7J	33869
@NP	L	33877
@NP	the density of CGRP-positive fibers	33887
@NP	the density	33887
@NP	CGRP-positive fibers	33902
@NP	highest inside the transplant with Vehicle -- OEC treatment	33927
@NP	highest inside the transplant with Vehicle	33927
@NP	highest	33927
@NP	the transplant with Vehicle	33942
@NP	the transplant	33942
@NP	Vehicle	33962
@NP	OEC treatment	33970
@NP	the combination of OECs with BDNF	33985
@NP	the combination	33985
@NP	OECs with BDNF	34004
@NP	OECs	34004
@NP	BDNF	34014
@NP	significantly more CGRP-positive axons	34031
@NP	1.5 mm rostral to the lesion	34085
@NP	1.5 mm rostral	34085
@NP	the lesion	34103
@NP	the OECs grafts -LRB- Fig. 7K and L -RRB-	34119
@NP	the OECs grafts	34119
@NP	Fig. 7K and L	34136
@NP	Fig. 7K	34136
@NP	L	34148
@NP	OEC grafts	34158
@NP	pronounced effects on the sprouting of SERT - , TH - and CGRPpositive axons	34173
@NP	pronounced effects on the sprouting of SERT -	34173
@NP	pronounced effects	34173
@NP	the sprouting of SERT -	34195
@NP	the sprouting	34195
@NP	SERT	34212
@NP	TH	34219
@NP	CGRPpositive axons	34227
@NP	the growth of the latter population	34251
@NP	the growth	34251
@NP	the latter population	34265
@NP	the application of BDNF	34303
@NP	the application	34303
@NP	BDNF	34322
@NP	the vicinity of the red nucleus in the midbrain	34330
@NP	the vicinity	34330
@NP	the red nucleus in the midbrain	34346
@NP	the red nucleus	34346
@NP	the midbrain	34365
@NP	Functional outcomes	34379
@NP	the behavioral outcomes	34409
@NP	our treatments on forelimb function on the left	34436
@NP	our treatments	34436
@NP	forelimb function on the left	34454
@NP	forelimb function	34454
@NP	the left	34475
@NP	side of the spinal cord	34494
@NP	side	34494
@NP	the spinal cord	34502
@NP	we	34519
@NP	the usage	34532
@NP	the left forelimb for the cylinder test and the food-pellet reaching task	34545
@NP	the left forelimb for the cylinder test	34545
@NP	the left forelimb	34545
@NP	the cylinder test	34567
@NP	the food-pellet reaching task	34589
@NP	the food-pellet	34589
@NP	task	34614
@NP	Figure 8A	34620
@NP	the time course of forelimb usage	34642
@NP	the time course	34642
@NP	forelimb usage	34661
@NP	vertical exploration of a Plexiglas cylinder	34683
@NP	vertical exploration	34683
@NP	a Plexiglas cylinder	34707
@NP	the usage of the left forelimb	34744
@NP	the usage	34744
@NP	the left forelimb	34757
@NP	left plus both	34789
@NP	left	34789
@NP	both	34799
@NP	rats	34826
@NP	25 %	34845
@NP	the left or right forelimb	34854
@NP	50 % with both simultaneously	34889
@NP	50 %	34889
@NP	control values	34926
@NP	75 -- 80 % for all groups	34958
@NP	75	34958
@NP	80 % for all groups	34961
@NP	80 %	34961
@NP	all groups	34969
@NP	spinal cord injury	34987
@NP	the literature -LRB- Liu et al. , 1999 ; Schallert et al. , 2000 -RRB-	35023
@NP	the literature	35023
@NP	Liu	35039
@NP	et al. , 1999 ; Schallert et al. , 2000	35043
@NP	et al.	35043
@NP	1999 ; Schallert et al.	35051
@NP	1999	35051
@NP	Schallert et al.	35057
@NP	Schallert	35057
@NP	et al.	35067
@NP	2000	35075
@NP	spinal cord injury	35088
@NP	the forelimb usage	35108
@NP	30	35152
@NP	40 % in rats , who received control treatment or any of the two monotreatments	35155
@NP	40 %	35155
@NP	rats , who received control treatment or any of the two monotreatments	35162
@NP	rats	35162
@NP	control treatment or any of the two monotreatments	35181
@NP	control treatment	35181
@NP	any of the two monotreatments	35202
@NP	any	35202
@NP	the two monotreatments	35209
@NP	it	35247
@NP	5 %	35273
@NP	rats treated with the combinatorial treatment of BDNF and OECs	35279
@NP	rats	35279
@NP	the combinatorial treatment of BDNF and OECs	35297
@NP	the combinatorial treatment	35297
@NP	BDNF and OECs	35328
@NP	the left forelimb	35359
@NP	95 % of the rears	35404
@NP	95 %	35404
@NP	the rears	35411
@NP	the right paw	35441
@NP	This diminution in the use of the left forelimb in BDNF -- OEC-treated rats	35456
@NP	This diminution	35456
@NP	the use of the left forelimb in BDNF -- OEC-treated rats	35475
@NP	the use	35475
@NP	the left forelimb in BDNF -- OEC-treated rats	35486
@NP	the left forelimb in BDNF	35486
@NP	the left forelimb	35486
@NP	BDNF	35507
@NP	OEC-treated rats	35512
@NP	the first 2 weeks	35546
@NP	injury -LRB- equivalent to the flow period of the osmotic minipump -RRB-	35570
@NP	injury	35570
@NP	the flow period of the osmotic minipump	35592
@NP	the flow period	35592
@NP	the osmotic minipump	35611
@NP	the usage	35650
@NP	the levels of other groups	35682
@NP	the levels	35682
@NP	other groups	35696
@NP	The rats	35710
@NP	a more sophisticated motor task	35740
@NP	proximal as well as distal muscles : the food-pellet reaching task	35782
@NP	proximal as well as distal muscles	35782
@NP	the food-pellet reaching task	35818
@NP	the food-pellet	35818
@NP	task	35843
@NP	Chan	35849
@NP	et al. , 2005	35854
@NP	et al.	35854
@NP	2005	35862
@NP	Figure 8B	35869
@NP	the time course	35891
@NP	motor skill changes for the food-pellet reaching task scaled on 10 points	35910
@NP	motor skill changes	35910
@NP	the food-pellet reaching task scaled on 10 points	35934
@NP	the food-pellet	35934
@NP	task scaled on 10 points	35959
@NP	task	35959
@NP	10 points	35974
@NP	injury	35992
@NP	all rats	36000
@NP	touch , grasp	36037
@NP	touch	36037
@NP	grasp	36044
@NP	the food pellet	36063
@NP	average score of 8 , see Chan et al. , 2005 for details of the scale	36080
@NP	average score	36080
@NP	8 , see Chan et al. , 2005 for details of the scale	36097
@NP	8	36097
@NP	Chan	36104
@NP	et al. , 2005 for details of the scale	36109
@NP	et al.	36109
@NP	2005 for details of the scale	36117
@NP	2005	36117
@NP	details of the scale	36126
@NP	details	36126
@NP	the scale	36137
@NP	spinal cord injury	36155
@NP	control rats as well as OEC-treated rats	36175
@NP	control rats	36175
@NP	control	36175
@NP	rats	36183
@NP	OEC-treated rats	36199
@NP	the pellet	36253
@NP	it -LRB- score 3 -RRB- during the first 3 weeks	36285
@NP	it -LRB- score 3 -RRB-	36285
@NP	it	36285
@NP	score 3	36289
@NP	the first 3 weeks	36305
@NP	4 weeks	36339
@NP	they	36347
@NP	score 5	36385
@NP	score 7	36423
@NP	the food pellet	36432
@NP	contrast	36452
@NP	BDNF -- OEC-treated rats	36462
@NP	BDNF	36462
@NP	OEC-treated rats	36467
@NP	injury compared with the control group	36523
@NP	injury	36523
@NP	the control group	36544
@NP	their left injured forelimb	36592
@NP	average score of 2	36646
@NP	average score	36646
@NP	2	36663
@NP	the 4 weeks of observation	36673
@NP	the 4 weeks	36673
@NP	observation	36688
@NP	BDNF-treated rats	36707
@NP	the second and third week in comparison	36770
@NP	the second and third week	36770
@NP	comparison	36799
@NP	OECtreated and control rats	36813
@NP	they	36842
@NP	the OEC-treated -LRB- P > 0.95 -RRB- and control -LRB- P = 0.3 -RRB-	36905
@NP	the OEC-treated	36905
@NP	P > 0.95	36922
@NP	P	36922
@NP	> 0.95	36924
@NP	>	36924
@NP	0.95	36926
@NP	control	36936
@NP	P	36945
@NP	0.3	36949
@NP	rats by 4 weeks	36954
@NP	rats	36954
@NP	4 weeks	36962
@NP	These observations	36971
@NP	the functional impairments observed in the cylinder and reaching tests	37004
@NP	the functional impairments	37004
@NP	the cylinder	37043
@NP	tests	37069
@NP	the combination of OEC transplants and BDNF	37094
@NP	the combination	37094
@NP	OEC transplants and BDNF	37113
@NP	OEC transplants	37113
@NP	BDNF	37133
@NP	this delay and diminution	37150
@NP	the functional motor recovery of the left injured forelimb	37179
@NP	the functional motor recovery	37179
@NP	the left injured forelimb	37212
@NP	we	37239
@NP	this	37257
@NP	a sensory alteration in the forepaws	37278
@NP	a sensory alteration	37278
@NP	the forepaws	37302
@NP	Figure 8C and D	37316
@NP	time courses of sensory thresholds to mechanical and thermal stimulation	37344
@NP	time courses	37344
@NP	sensory thresholds to mechanical and thermal stimulation	37360
@NP	sensory thresholds	37360
@NP	mechanical and thermal stimulation	37382
@NP	spinal cord injury and treatment	37434
@NP	BDNF-treated or OEC-treated rats	37477
@NP	a decreased mechanical and thermal threshold	37520
@NP	rats	37590
@NP	P = 0.26 and P = 0.2 for weeks 2 and 3 , respectively , in Fig. 8D	37596
@NP	P = 0.26	37596
@NP	P	37596
@NP	= 0.26	37598
@NP	P = 0.2 for weeks 2 and 3 , respectively , in Fig. 8D	37609
@NP	P	37609
@NP	0.2	37613
@NP	weeks 2 and 3 , respectively , in Fig. 8D	37621
@NP	weeks 2 and 3 , respectively ,	37621
@NP	weeks 2 and 3	37621
@NP	Fig. 8D	37653
@NP	BDNF	37668
@NP	OEC-treated rats	37674
@NP	a significant diminution	37698
@NP	sensory thermal thresholds	37726
@NP	the duration of the cell body treatment in comparison	37757
@NP	the duration	37757
@NP	the cell body treatment in comparison	37773
@NP	the cell body treatment	37773
@NP	comparison	37800
@NP	the control rats	37816
@NP	this	37838
@NP	the other groups	37872
@NP	4 weeks after spinal cord injury and treatment -LRB- P = 0.07 -RRB-	37892
@NP	4 weeks	37892
@NP	spinal cord injury and treatment -LRB- P = 0.07 -RRB-	37906
@NP	spinal cord injury and treatment	37906
@NP	P	37940
@NP	0.07	37944
@NP	the motor scores	37960
@NP	the sensory thresholds	37985
@NP	a strong correlation -LRB- R = 0.58 , P < 0.01 -RRB-	38017
@NP	a strong correlation	38017
@NP	R = 0.58 , P < 0.01	38039
@NP	R	38039
@NP	= 0.58 , P < 0.01	38041
@NP	= 0.58 , P <	38041
@NP	0.58 , P	38043
@NP	0.58	38043
@NP	P	38049
@NP	0.01	38053
@NP	poor motor performances and low thermal thresholds in individual BDNF --	38067
@NP	poor motor performances	38067
@NP	low thermal thresholds in individual BDNF	38095
@NP	low thermal thresholds	38095
@NP	individual BDNF	38121
@NP	OEC rats -LRB- Fig. 9 -RRB-	38137
@NP	OEC rats	38137
@NP	Fig. 9	38147
@NP	the delay and diminution in functional recovery	38162
@NP	the delay and diminution	38162
@NP	functional recovery	38190
@NP	BDNF	38222
@NP	OEC rats	38227
@NP	an alteration in mechanical and thermal sensations	38263
@NP	an alteration	38263
@NP	mechanical and thermal sensations	38280
@NP	Discussion Combinatorial treatments	38316
@NP	the multifaceted problems	38388
@NP	spinal cord injury	38434
@NP	Lu	38454
@NP	et al. , 2003	38457
@NP	et al.	38457
@NP	2003	38465
@NP	Nikulina et al. , 2004	38471
@NP	Nikulina	38471
@NP	et al. , 2004	38480
@NP	et al.	38480
@NP	2004	38488
@NP	Pearse et al. , 2004	38494
@NP	Pearse	38494
@NP	et al. , 2004	38501
@NP	et al.	38501
@NP	2004	38509
@NP	Fouad et al. , 2005	38515
@NP	Fouad	38515
@NP	et al. , 2005	38521
@NP	et al.	38521
@NP	2005	38529
@NP	Steinmetz et al. , 2005	38535
@NP	Steinmetz	38535
@NP	et al. , 2005	38545
@NP	et al.	38545
@NP	2005	38553
@NP	we	38565
@NP	the first time	38579
@NP	the potential for detrimental effects of a combinatorial therapy	38594
@NP	the potential	38594
@NP	detrimental effects of a combinatorial therapy	38612
@NP	detrimental effects	38612
@NP	a combinatorial therapy	38635
@NP	We	38660
@NP	transplantation of highly enriched LP-derived OECs -LRB- LPOECs -RRB-	38672
@NP	transplantation	38672
@NP	highly enriched LP-derived OECs -LRB- LPOECs -RRB-	38691
@NP	highly enriched LP-derived OECs	38691
@NP	LPOECs	38724
@NP	cervical spinal cord injury sites of rats with the infusion of BDNF	38737
@NP	cervical spinal cord injury sites	38737
@NP	rats with the infusion of BDNF	38774
@NP	rats	38774
@NP	the infusion of BDNF	38784
@NP	the infusion	38784
@NP	BDNF	38800
@NP	the red nucleus	38808
@NP	All treatment groups	38825
@NP	BDNF	38852
@NP	OECs	38864
@NP	BDNF -- OECs	38879
@NP	BDNF	38879
@NP	OECs	38884
@NP	the lesion size of the spinal cord	38906
@NP	the lesion size	38906
@NP	the spinal cord	38925
@NP	the both groups with OECs	38946
@NP	the both groups	38946
@NP	OECs	38967
@NP	cavitation and astrocytic hypertrophy	38980
@NP	cavitation	38980
@NP	astrocytic hypertrophy	38995
@NP	Each treatment alone as well as in combination	39019
@NP	Each treatment	39019
@NP	combination	39054
@NP	the number of rubrospinal axons rostral	39076
@NP	the number	39076
@NP	rubrospinal axons rostral	39090
@NP	the lesion site	39119
@NP	no group	39145
@NP	rubrospinal axon regeneration	39161
@NP	the OECs	39199
@NP	the distal spinal cord	39213
@NP	surprisingly the combinatorial treatment	39246
@NP	addition	39291
@NP	no further benefits	39311
@NP	single treatment	39338
@NP	impaired functional recovery	39356
@NP	the forelimb	39388
@NP	the injury side -LRB- left -RRB-	39404
@NP	the injury side	39404
@NP	left	39421
@NP	hypersensitivity of the forepaw	39450
@NP	hypersensitivity	39450
@NP	the forepaw	39470
@NP	The neuroprotective effects of transplanting neonatal LP-OECs	39483
@NP	The neuroprotective effects	39483
@NP	neonatal LP-OECs	39528
@NP	previous observations	39590
@NP	adult rat OB-derived OECs	39618
@NP	the injured dorsolateral funiculus in Fischer rats	39647
@NP	the injured dorsolateral funiculus	39647
@NP	Fischer rats	39685
@NP	Ruitenberg et al. , 2003	39699
@NP	Ruitenberg	39699
@NP	et al.	39710
@NP	2003	39718
@NP	transduction of OB-OECs with BDNF and ⁄ or NT-3-expressing viral vectors	39740
@NP	transduction	39740
@NP	OB-OECs with BDNF and ⁄ or NT-3-expressing viral vectors	39756
@NP	OB-OECs	39756
@NP	BDNF and ⁄ or NT-3-expressing viral vectors	39769
@NP	BDNF and ⁄	39769
@NP	NT-3-expressing viral vectors	39783
@NP	they	39814
@NP	lesion volumes	39827
@NP	the spinal cord cytoarchitecture	39856
@NP	the injured dorsolateral funiculus	39892
@NP	Ruitenberg et al. , 2003	39928
@NP	Ruitenberg	39928
@NP	et al.	39939
@NP	2003	39947
@NP	Our combination of LP-OECs with BDNF infusion to the midbrain	39954
@NP	Our combination	39954
@NP	LP-OECs with BDNF infusion to the midbrain	39973
@NP	LP-OECs	39973
@NP	BDNF infusion to the midbrain	39986
@NP	BDNF infusion	39986
@NP	the midbrain	40003
@NP	significant neuroprotective effects	40032
@NP	the trend with each single treatment	40076
@NP	the trend	40076
@NP	each single treatment	40091
@NP	no apparent additive effects	40125
@NP	All three treatment groups	40155
@NP	more rubrospinal axons	40189
@NP	close vicinity	40215
@NP	the epicenter	40233
@NP	less axonal retraction ⁄ dieback and ⁄	40268
@NP	the control group	40333
@NP	It	40352
@NP	these two scenarios in our experiments	40386
@NP	these two scenarios	40386
@NP	our experiments	40409
@NP	The straight course	40426
@NP	many rubrospinal axons in their original localization within the tract	40449
@NP	many rubrospinal axons	40449
@NP	their original localization within the tract	40475
@NP	their original localization	40475
@NP	the tract	40510
@NP	the interpretation of axonal protection -LRB- i.e. less retraction -RRB-	40527
@NP	the interpretation	40527
@NP	axonal protection -LRB- i.e. less retraction -RRB-	40549
@NP	axonal protection	40549
@NP	i.e. less retraction	40568
@NP	i.e.	40568
@NP	less retraction	40573
@NP	retraction and regrowth	40602
@NP	the effects of BDNF plus OECs	40634
@NP	the effects	40634
@NP	BDNF plus OECs	40649
@NP	BDNF	40649
@NP	OECs	40659
@NP	the prevention of retraction	40687
@NP	the prevention	40687
@NP	retraction	40705
@NP	BDNF or OEC application	40738
@NP	Rubrospinal axons	40769
@NP	the transplanted cells	40819
@NP	the site	40845
@NP	OEC injection	40857
@NP	the injury	40883
@NP	the cells that filled the lesion site	40917
@NP	the cells	40917
@NP	the lesion site	40939
@NP	we	40962
@NP	transplanted cells	40988
@NP	the axonal stumps of the rubrospinal tract	41035
@NP	the axonal stumps	41035
@NP	the rubrospinal tract	41056
@NP	⁄ or some rubrospinal axons	41083
@NP	⁄	41083
@NP	some rubrospinal axons	41088
@NP	the transplanted cells	41139
@NP	there	41163
@NP	no evidence for rubrospinal regeneration	41173
@NP	no evidence	41173
@NP	rubrospinal regeneration	41189
@NP	the injury site	41229
@NP	These findings	41246
@NP	line	41268
@NP	the observations	41278
@NP	Ruitenberg and co-workers	41298
@NP	no sprouting of rubrospinal axons	41335
@NP	no sprouting	41335
@NP	rubrospinal axons	41351
@NP	adult OB-OEC-filled lesion sites	41374
@NP	these	41415
@NP	trophic factors -LRB- Ruitenberg et al. , 2003 -RRB-	41448
@NP	trophic factors	41448
@NP	Ruitenberg	41465
@NP	et al. , 2003	41476
@NP	et al.	41476
@NP	2003	41484
@NP	Our BDNF treatments	41984
@NP	rubrospinal axon growth	42029
@NP	the transplants	42058
@NP	There	42075
@NP	most likely differences	42085
@NP	the neurotrophic ⁄	42117
@NP	tropic effects	42136
@NP	BDNF overexpressed by transplanted cells -LRB- Ruitenberg et al. , 2003 -RRB-	42154
@NP	BDNF	42154
@NP	transplanted cells -LRB- Ruitenberg et al. , 2003 -RRB-	42176
@NP	transplanted cells	42176
@NP	Ruitenberg	42196
@NP	et al. , 2003	42207
@NP	et al.	42207
@NP	2003	42215
@NP	vs.	42221
@NP	BDNF	42225
@NP	the cell bodies	42249
@NP	the growing rubrospinal axons	42290
@NP	BDNF infusion to the red nucleus	42321
@NP	BDNF infusion	42321
@NP	the red nucleus	42338
@NP	BDNF mRNA	42364
@NP	these neurons -LRB- Kobayashi et al. , 1997 -RRB-	42377
@NP	these neurons	42377
@NP	Kobayashi	42392
@NP	et al. , 1997	42402
@NP	et al.	42402
@NP	1997	42410
@NP	the first scenario	42420
@NP	the transplanted cells	42440
@NP	a gradient	42474
@NP	BDNF	42489
@NP	a neurotropic attractant in the lesion center	42505
@NP	a neurotropic attractant	42505
@NP	the lesion center	42533
@NP	the latter scenario	42561
@NP	the source	42581
@NP	the axons of the proximal tract themselves	42601
@NP	the axons	42601
@NP	the proximal tract themselves	42614
@NP	the proximal tract	42614
@NP	the gradient	42645
@NP	such attraction into the lesion	42671
@NP	such attraction	42671
@NP	the lesion	42692
@NP	our previous studies	42730
@NP	we	42751
@NP	stimulation of rubrospinal axon growth	42763
@NP	stimulation	42763
@NP	rubrospinal axon growth	42778
@NP	peripheral nerve transplants	42807
@NP	BDNF cell body treatment	42841
@NP	Kobayashi	42867
@NP	et al. , 1997 ; Kwon et al. , 2002	42877
@NP	et al.	42877
@NP	1997 ; Kwon et al.	42885
@NP	1997	42885
@NP	Kwon et al.	42891
@NP	Kwon	42891
@NP	et al.	42896
@NP	2002	42904
@NP	contrast	42920
@NP	no stimulation of rubrospinal sprouting into the OEC-filled lesion sites	42929
@NP	no stimulation	42929
@NP	rubrospinal sprouting into the OEC-filled lesion sites	42947
@NP	the OEC-filled lesion	42974
@NP	this treatment in the present study	43020
@NP	this treatment	43020
@NP	the present study	43038
@NP	The survival time in these former studies	43057
@NP	The survival time	43057
@NP	these former studies	43078
@NP	> 10 weeks	43111
@NP	>	43111
@NP	10 weeks	43113
@NP	the present study , which could have played some role	43131
@NP	the present study	43131
@NP	some role	43174
@NP	longer survival times	43191
@NP	more regeneration	43236
@NP	we	43255
@NP	time for regeneration	43268
@NP	time	43268
@NP	regeneration	43277
@NP	the main reason for these differences	43297
@NP	the main reason	43297
@NP	these differences	43317
@NP	our hands	43342
@NP	some rubrospinal axons	43352
@NP	peripheral nerve transplants	43391
@NP	a month -LRB- unpublished data , W.T. -RRB-	43427
@NP	a month	43427
@NP	unpublished data	43436
@NP	W.T.	43454
@NP	These findings	43461
@NP	important differences	43486
@NP	these two types of bridges , including the fact that our OECs were	43516
@NP	these two types	43516
@NP	bridges	43535
@NP	the fact that our OECs were	43554
@NP	the fact	43554
@NP	our OECs	43568
@NP	an enriched population	43587
@NP	OECs	43613
@NP	a mixture of cells with extensive extracellular matrix encountered in a nerve	43630
@NP	a mixture	43630
@NP	cells with extensive extracellular matrix encountered in a nerve	43643
@NP	cells	43643
@NP	extensive extracellular matrix encountered in a nerve	43654
@NP	extensive extracellular matrix	43654
@NP	a nerve	43700
@NP	-LRB- 2 -RRB- randomly oriented rather than aligned by long basal lamina tubes	43709
@NP	randomly	43713
@NP	long basal lamina tubes	43754
@NP	a	43783
@NP	mouse-to-rat xenograft	43785
@NP	that may stimulate an adverse immune response rather than a nerve autograft	43808
@NP	that may stimulate an adverse immune response	43808
@NP	an adverse immune response	43827
@NP	a nerve autograft	43866
@NP	-LRB- 4 -RRB- a possibly weaker source of trophic ⁄ tropic factors	43889
@NP	a possibly weaker source	43893
@NP	trophic ⁄ tropic factors	43921
@NP	peripheral nerve grafts	43951
@NP	A recent report by Xiao et al. -LRB- 2007 -RRB-	43976
@NP	A recent report by Xiao et al.	43976
@NP	A recent report by Xiao	43976
@NP	A recent report	43976
@NP	Xiao	43995
@NP	et al.	44000
@NP	2007	44008
@NP	extensive rubrospinal regeneration	44022
@NP	transplantation	44063
@NP	a cell line	44082
@NP	human adult olfactory neuroepithelial progenitors cells	44107
@NP	human adult olfactory neuroepithelial progenitors	44107
@NP	cells	44157
@NP	up to 40 passages	44176
@NP	these cells	44201
@NP	epigenetic events	44231
@NP	an immortalized line -LRB- now commercialized by RhinoCytes -RRB-	44263
@NP	an	44263
@NP	line -LRB- now commercialized by RhinoCytes -RRB-	44279
@NP	line	44279
@NP	RhinoCytes	44307
@NP	primary cultures of OECs	44320
@NP	primary cultures	44320
@NP	OECs	44340
@NP	sphere-forming behavior and bear little similarity	44357
@NP	these	44413
@NP	cells.We	44432
@NP	an independent replication	44455
@NP	the extensive rubrospinal regeneration claimed by these authors	44485
@NP	the extensive rubrospinal regeneration	44485
@NP	these authors	44535
@NP	We	44550
@NP	functional recovery ⁄ compensation	44568
@NP	recovery ⁄	44579
@NP	a cylinder	44606
@NP	task	44630
@NP	newborn mouse LP-OEC transplants in contrast	44638
@NP	newborn mouse LP-OEC transplants	44638
@NP	contrast	44674
@NP	previous studies	44686
@NP	behavioral improvement	44717
@NP	a ropewalking task after adult rat OB-OECs transplants	44743
@NP	a ropewalking task	44743
@NP	adult rat OB-OECs transplants	44768
@NP	Li	44799
@NP	et al. , 1997 , 1998 ; Ruitenberg et al. , 2003 ; Sasaki et al. , 2004	44802
@NP	et al.	44802
@NP	1997 , 1998 ; Ruitenberg et al. , 2003 ; Sasaki et al.	44810
@NP	1997 , 1998	44810
@NP	1997	44810
@NP	1998	44816
@NP	Ruitenberg et al. , 2003	44822
@NP	Ruitenberg	44822
@NP	et al. , 2003	44833
@NP	et al.	44833
@NP	2003	44841
@NP	Sasaki et al.	44847
@NP	Sasaki	44847
@NP	et al.	44854
@NP	2004	44862
@NP	This difference	44869
@NP	intrinsic differences between cell types -LRB- LP vs.	44901
@NP	intrinsic differences	44901
@NP	cell types -LRB- LP vs.	44931
@NP	cell types	44931
@NP	LP	44943
@NP	OB ; Au & Roskams , 2003	44950
@NP	OB	44950
@NP	Au & Roskams , 2003	44954
@NP	Au & Roskams	44954
@NP	2003	44968
@NP	Richter et al. , 2005 -RRB-	44974
@NP	Richter	44974
@NP	et al.	44982
@NP	2005	44990
@NP	the age -LRB- neonatal vs. adult donors ; Lipson et al. , 2003 -RRB-	44999
@NP	the age	44999
@NP	neonatal vs. adult donors ; Lipson et al. , 2003	45008
@NP	neonatal	45008
@NP	adult donors ; Lipson et al.	45021
@NP	adult donors	45021
@NP	Lipson et al.	45035
@NP	Lipson	45035
@NP	et al.	45042
@NP	2003	45050
@NP	xenotransplant side effects and the behavioral test	45060
@NP	xenotransplant side effects	45060
@NP	the behavioral test	45092
@NP	the combination	45135
@NP	OECs transplants with BDNF treatment of rubrospinal neurons impaired	45154
@NP	OECs transplants	45154
@NP	BDNF treatment of rubrospinal neurons impaired	45176
@NP	BDNF treatment	45176
@NP	rubrospinal neurons impaired	45194
@NP	rubrospinal neurons	45194
@NP	functional recovery	45235
@NP	This apparent motor impairment	45256
@NP	sensory hypersensitivity	45303
@NP	the duration of the cell body treatment	45332
@NP	the duration	45332
@NP	the cell body treatment	45348
@NP	the density of CGRP-positive axons in the spinal cord	45386
@NP	the density	45386
@NP	CGRP-positive axons in the spinal cord	45401
@NP	CGRP-positive axons	45401
@NP	the spinal cord	45424
@NP	the lesion in the combined BDNF -- OEC treatment group	45452
@NP	the lesion in the combined BDNF	45452
@NP	the lesion	45452
@NP	the combined BDNF	45466
@NP	OEC treatment group	45484
@NP	mechanical and thermal hypersensitivity	45514
@NP	mechanical	45514
@NP	thermal hypersensitivity	45529
@NP	adult rat OB-OECs transplantations	45578
@NP	a photochemical lesion	45623
@NP	the spinal cord -LRB- Verdu et al. , 2003 ; Lopez - Vales et al. , 2004 -RRB-	45649
@NP	the spinal cord	45649
@NP	Verdu	45666
@NP	et al. , 2003 ; Lopez - Vales et al. , 2004	45672
@NP	et al.	45672
@NP	2003 ; Lopez - Vales et al.	45680
@NP	2003 ; Lopez	45680
@NP	2003	45680
@NP	Lopez	45686
@NP	Vales et al.	45693
@NP	Vales	45693
@NP	et al.	45699
@NP	2004	45707
@NP	we	45714
@NP	altered sensitivity thresholds	45730
@NP	our LP-OEC -LRB- vehicle -- OECs -RRB-	45764
@NP	our LP-OEC	45764
@NP	vehicle -- OECs	45776
@NP	vehicle	45776
@NP	OECs	45784
@NP	transplanted group	45796
@NP	Neither	45816
@NP	we	45828
@NP	lowered thresholds	45839
@NP	BDNF infusion alone -LRB- BDNF -- DMEM -RRB-	45864
@NP	BDNF infusion alone	45864
@NP	BDNF infusion	45864
@NP	BDNF -- DMEM	45885
@NP	BDNF	45885
@NP	DMEM	45891
@NP	the lowered sensory thresholds	45905
@NP	our combined OEC	45948
@NP	BDNF group	45965
@NP	an unexpected combinatorial effect	45988
@NP	We	46024
@NP	the possible mechanism	46049
@NP	It	46073
@NP	the combined group	46093
@NP	higher levels of trophic factors	46117
@NP	higher levels	46117
@NP	trophic factors	46134
@NP	the site of spinal cord injury than the single treatment groups	46153
@NP	the site	46153
@NP	spinal cord injury than the single treatment groups	46165
@NP	spinal cord injury	46165
@NP	the single treatment groups	46189
@NP	example	46222
@NP	adult hamster and rat OB-OECs	46231
@NP	different types	46282
@NP	neurotrophic factors	46301
@NP	BDNF and nerve growth factor -LRB- NGF -RRB-	46331
@NP	BDNF and nerve growth factor	46331
@NP	NGF	46361
@NP	Boruch	46367
@NP	et al. , 2001	46374
@NP	et al.	46374
@NP	2001	46382
@NP	Lipson et al. , 2003	46388
@NP	Lipson	46388
@NP	et al. , 2003	46395
@NP	et al.	46395
@NP	2003	46403
@NP	Sasaki et al. , 2006b	46409
@NP	Sasaki	46409
@NP	et al. , 2006b	46416
@NP	et al.	46416
@NP	2006b	46424
@NP	Wang et al. , 2006	46430
@NP	Wang	46430
@NP	et al. , 2006	46435
@NP	et al.	46435
@NP	2006	46443
@NP	Pastrana et al. , 2007	46449
@NP	Pastrana	46449
@NP	et al. , 2007	46458
@NP	et al.	46458
@NP	2007	46466
@NP	this	46477
@NP	the case for LP-OECs	46489
@NP	the case	46489
@NP	LP-OECs	46502
@NP	addition	46514
@NP	the exogenous delivery of BDNF at the red nucleus level	46524
@NP	the exogenous delivery	46524
@NP	BDNF at the red nucleus level	46550
@NP	BDNF	46550
@NP	the red nucleus level	46558
@NP	the mRNA expression of BDNF	46590
@NP	the mRNA expression	46590
@NP	BDNF	46613
@NP	rubrospinal neurons -LRB- Kobayashi et al. , 1997 -RRB-	46621
@NP	rubrospinal neurons	46621
@NP	Kobayashi	46642
@NP	et al. , 1997	46652
@NP	et al.	46652
@NP	1997	46660
@NP	spinal BDNF delivery via axonal transport	46687
@NP	spinal BDNF delivery	46687
@NP	axonal transport	46712
@NP	their terminals	46732
@NP	the literature	46758
@NP	conflicting	46776
@NP	BDNF	46789
@NP	sensitization	46817
@NP	dorsal horn neurons	46834
@NP	Kerr	46855
@NP	et al. , 1999	46860
@NP	et al.	46860
@NP	1999	46868
@NP	Mannion et al. , 1999	46874
@NP	Mannion	46874
@NP	et al. , 1999	46882
@NP	et al.	46882
@NP	1999	46890
@NP	Heppenstall & Lewin , 2001	46896
@NP	Heppenstall & Lewin	46896
@NP	2001	46917
@NP	Pezet et al. , 2002	46923
@NP	Pezet	46923
@NP	et al. , 2002	46929
@NP	et al.	46929
@NP	2002	46937
@NP	Coull et al. , 2005	46943
@NP	Coull	46943
@NP	et al. , 2005	46949
@NP	et al.	46949
@NP	2005	46957
@NP	the role of NGF in pain mechanisms	46968
@NP	the role	46968
@NP	NGF in pain mechanisms	46980
@NP	NGF	46980
@NP	pain mechanisms	46987
@NP	Christensen & Hulsebosch , 1997 ; Pezet et al.	47024
@NP	Christensen & Hulsebosch , 1997	47024
@NP	Christensen & Hulsebosch	47024
@NP	1997	47050
@NP	Pezet et al.	47056
@NP	Pezet	47056
@NP	et al.	47062
@NP	2001 ; Priestley et al.	47070
@NP	2001	47070
@NP	Priestley et al.	47076
@NP	Priestley	47076
@NP	et al.	47086
@NP	2002 ; Pezet & McMahon , 2006	47094
@NP	2002	47094
@NP	Pezet & McMahon , 2006	47100
@NP	Pezet & McMahon	47100
@NP	2006	47117
@NP	the infusion of BDNF	47134
@NP	the infusion	47134
@NP	BDNF	47150
@NP	the rostroventral medulla	47174
@NP	it	47206
@NP	nociceptive mechanisms	47229
@NP	BDNF infusions	47276
@NP	this area -LRB- Guo et al. , 2006 -RRB-	47296
@NP	this area	47296
@NP	Guo	47307
@NP	et al. , 2006	47311
@NP	et al.	47311
@NP	2006	47319
@NP	BDNF infusion to the red nucleus	47332
@NP	BDNF infusion	47332
@NP	the red nucleus	47349
@NP	an effect on sensory thresholds	47382
@NP	an effect	47382
@NP	sensory thresholds	47395
@NP	the absence of cell transplantation	47417
@NP	the absence	47417
@NP	cell transplantation	47432
@NP	such a mechanism involving the medulla	47454
@NP	such a mechanism	47454
@NP	the medulla	47481
@NP	the sensitization effect of dorsal horn neurons	47513
@NP	the sensitization effect	47513
@NP	dorsal horn neurons	47541
@NP	OECs transplants	47564
@NP	conclusion	47585
@NP	our transplants of highly enriched LP-OECs	47606
@NP	our transplants	47606
@NP	highly enriched LP-OECs	47625
@NP	the injured spinal cord	47657
@NP	astrocyte hypertrophy	47693
@NP	they	47716
@NP	regeneration of rubrospinal axons	47739
@NP	regeneration	47739
@NP	rubrospinal axons	47755
@NP	the lesion site	47792
@NP	addition	47812
@NP	the combination of highly enriched OECs with BDNF infusion to the red nucleus	47822
@NP	the combination	47822
@NP	highly enriched OECs with BDNF infusion to the red nucleus	47841
@NP	highly enriched OECs	47841
@NP	BDNF infusion to the red nucleus	47867
@NP	BDNF infusion	47867
@NP	the red nucleus	47884
@NP	the functional recovery	47923
@NP	lowered sensory thresholds	47970
@NP	the forepaw	48000
@NP	These adverse effects of a combinatorial treatment	48013
@NP	These adverse effects	48013
@NP	a combinatorial treatment	48038
@NP	contrast	48084
@NP	the beneficial effects	48107
@NP	other combinations	48142
@NP	Lu	48162
@NP	et al. , 2003	48165
@NP	et al.	48165
@NP	2003	48173
@NP	Nikulina et al. , 2004	48179
@NP	Nikulina	48179
@NP	et al. , 2004	48188
@NP	et al.	48188
@NP	2004	48196
@NP	Pearse et al. , 2004	48202
@NP	Pearse	48202
@NP	et al. , 2004	48209
@NP	et al.	48209
@NP	2004	48217
@NP	Fouad et al. , 2005	48223
@NP	Fouad	48223
@NP	et al. , 2005	48229
@NP	et al.	48229
@NP	2005	48237
@NP	Steinmetz et al. , 2005	48243
@NP	Steinmetz	48243
@NP	et al. , 2005	48253
@NP	et al.	48253
@NP	2005	48261
@NP	BDNF infusion into the midbrain	48268
@NP	BDNF infusion	48268
@NP	the midbrain	48287
@NP	axonal growth -LRB- Kobayashi et al. , 1997 ; Kwon et al. , 2002 -RRB-	48342
@NP	axonal growth	48342
@NP	Kobayashi	48357
@NP	et al. , 1997 ; Kwon et al. , 2002	48367
@NP	et al.	48367
@NP	1997 ; Kwon et al.	48375
@NP	1997	48375
@NP	Kwon et al.	48381
@NP	Kwon	48381
@NP	et al.	48386
@NP	2002	48394
@NP	therapeutic potential in its present form	48419
@NP	therapeutic potential	48419
@NP	its present form	48444
@NP	it	48464
@NP	fine motor recovery	48477
@NP	Alternatives	48498
@NP	the enhancement of the intrinsic growth response of these neurons	48515
@NP	the enhancement	48515
@NP	the intrinsic growth response of these neurons	48534
@NP	the intrinsic growth response	48534
@NP	these neurons	48567
@NP	that	48592
@NP	adverse effects	48622
@NP	combinations	48652
@NP	the observed changes in motor and sensory function after combination therapy	48672
@NP	the observed changes	48672
@NP	motor and sensory function after combination therapy	48696
@NP	motor and sensory function	48696
@NP	combination therapy	48729
@NP	the necessity for extensive sensory	48759
@NP	the necessity	48759
@NP	extensive sensory	48777
@NP	motor testing	48799
@NP	candidate combination strategies	48816
@NP	some benefits	48876
@NP	Acknowledgements F.	48898
@NP	Bretzner	48918
@NP	a Fonds de Recherche en Sante du Quebec -LRB- FRSQ -RRB-	48941
@NP	a Fonds de Recherche	48941
@NP	Sante du Quebec -LRB- FRSQ -RRB-	48965
@NP	Sante du Quebec	48965
@NP	FRSQ	48982
@NP	Canadian Institutes of Health Research -LRB- CIHR -RRB- post-doctoral fellowship	48992
@NP	Canadian Institutes of Health Research -LRB- CIHR -RRB-	48992
@NP	Canadian Institutes	48992
@NP	Health Research -LRB- CIHR -RRB-	49015
@NP	Health Research	49015
@NP	CIHR	49032
@NP	post-doctoral fellowship	49038
@NP	This work	49064
@NP	-LRB- CIHR -RRB-	49088
@NP	Christopher	49096
@NP	Dana Reeve Foundation and International Spinal Research Trust	49112
@NP	We	49175
@NP	Tigran Bajgoric , Clarrie Lam , Miranda Richter and Darren Sutherland	49198
@NP	Tigran Bajgoric	49198
@NP	Clarrie Lam	49215
@NP	Miranda Richter	49228
@NP	Darren Sutherland	49248
@NP	technical assistance	49270
@NP	Abbreviations BDA , biotinylated dextran amine	49293
@NP	Abbreviations BDA	49293
@NP	Abbreviations	49293
@NP	BDA	49307
@NP	dextran amine	49325
@NP	BDNF , brain-derived neurotrophic factor	49340
@NP	BDNF	49340
@NP	brain-derived neurotrophic factor	49346
@NP	CGRP , calcitonin gene-related peptide	49381
@NP	CGRP	49381
@NP	calcitonin gene-related peptide	49387
@NP	FBS , fetal bovine serum	49420
@NP	FBS	49420
@NP	fetal bovine serum	49425
@NP	GFAP , glial fibrillary acidic protein	49445
@NP	GFAP	49445
@NP	glial fibrillary acidic protein	49451
@NP	GFP , green fluorescent protein	49484
@NP	GFP	49484
@NP	green fluorescent protein	49489
@NP	LP , lamina-propria	49516
@NP	LP	49516
@NP	lamina-propria	49520
@NP	NF , neurofilament	49536
@NP	NF	49536
@NP	neurofilament	49540
@NP	NGF , nerve growth factor	49555
@NP	NGF	49555
@NP	nerve growth factor	49560
@NP	OB , olfactory bulb	49581
@NP	OB	49581
@NP	olfactory bulb	49585
@NP	OEC , olfactory ensheathing cells	49601
@NP	OEC	49601
@NP	olfactory ensheathing cells	49606
@NP	P ⁄ S , penicillin ⁄ streptomycin	49635
@NP	P ⁄ S	49635
@NP	penicillin ⁄ streptomycin	49642
@NP	PBS , phosphate-buffered saline	49669
@NP	PBS	49669
@NP	phosphate-buffered saline	49674
@NP	SERT , serotonin transporter	49701
@NP	SERT	49701
@NP	serotonin transporter	49707
@NP	Sub-P , substance-P	49730
@NP	Sub-P	49730
@NP	substance-P	49737
@NP	TH , tyrosine hydroxylase	49750
@NP	TH	49750
@NP	tyrosine hydroxylase	49754
@NP	Tub , beta-III-tubulin	49776
@NP	Tub	49776
@NP	beta-III-tubulin	49781
@NP	Veh , vehicle	49799
@NP	Veh	49799
@NP	vehicle	49804
@NP	References	49813
@NP	Amador , M.J. & Guest , J.D. -LRB- 2005 -RRB-	49824
@NP	Amador , M.J. & Guest	49824
@NP	J.D. -LRB- 2005 -RRB-	49846
@NP	J.D.	49846
@NP	2005	49852
@NP	An appraisal of ongoing experimental procedures in human spinal cord injury	49858
@NP	An appraisal	49858
@NP	ongoing experimental procedures in human spinal cord injury	49874
@NP	ongoing experimental procedures	49874
@NP	human spinal cord injury	49909
@VP	to promote axonal regeneration and functional recovery after spinal cord injury	581
@VP	promote axonal regeneration and functional recovery after spinal cord injury	584
@VP	undergo massive atrophy after cervical axotomy	801
@VP	show only transient expression of regenerationassociated genes	852
@VP	prevents this atrophy	982
@VP	stimulates regenerationassociated gene expression	1005
@VP	promotes regeneration of rubrospinal axons into peripheral nerve transplants	1059
@VP	to regenerate through a bridge of OEC transplants	1197
@VP	regenerate through a bridge of OEC transplants	1200
@VP	was due to this weak intrinsic cell body response	1247
@VP	derived from the nasal mucosa	1400
@VP	prevented the dieback of the rubrospinal axons	1590
@VP	promoted rubrospinal regeneration beyond the lesion ⁄ transplantation site	1655
@VP	were more impaired after combining transplantation of OECs with BDNF treatment	1843
@VP	combining transplantation of OECs with BDNF treatment	1868
@VP	receiving the combinatorial therapy	2009
@VP	were not seen with each treatment alone	2053
@VP	seen with each treatment alone	2062
@VP	may have undesired effects in the injured spinal cord	2300
@VP	have undesired effects in the injured spinal cord	2304
@VP	derived from the olfactory bulb	2404
@VP	shown that lamina-propria -LRB- LP -RRB-	3171
@VP	derived from the OB in vitro	3285
@VP	engrafted mouse LP-OECs but not beyond -LRB- Ramer et al. , 2004a -RRB-	3551
@VP	to regenerate	3761
@VP	regenerate	3764
@VP	prevented the atrophy of rubrospinal neurons	3993
@VP	stimulated the expression of regeneration - associated genes	4039
@VP	associated genes	4082
@VP	initiated 1 year after spinal cord injury -LRB- Kwon et al. , 2002 -RRB-	4324
@VP	promote regeneration of rubrospinal axons into and beyond a LP-OEC transplant	4489
@VP	To assess this	4670
@VP	assess this	4673
@VP	derived from the nasal mucosa of green fluorescent protein	4754
@VP	delivering BDNF for 2 weeks	4890
@VP	enhanced some regenerative sprouting of rubrospinal axons	4947
@VP	sprouting of rubrospinal axons	4974
@VP	failed to promote their regeneration through engrafted LP-OECs	5009
@VP	to promote their regeneration through engrafted LP-OECs	5016
@VP	promote their regeneration through engrafted LP-OECs	5019
@VP	engrafted LP-OECs	5054
@VP	diminished	5110
@VP	correlated with decreased sensory thresholds	5188
@VP	is detailed elsewhere	5329
@VP	detailed elsewhere	5332
@VP	killed by decapitation	5466
@VP	performed using anti-Thy1.1-mediated complement lysis	6244
@VP	using anti-Thy1.1-mediated complement lysis	6254
@VP	to remove the majority of contaminating fibroblasts	6298
@VP	remove the majority of contaminating fibroblasts	6301
@VP	replated in DMEM ⁄ F-12 , 10 % FBS and 100 U ⁄ mL P ⁄ S	6362
@VP	subjected to Thy1 .1	6484
@VP	mediated complement lysis	6505
@VP	grown in the same media for an additional 24	6535
@VP	plated on to plastic coverslips	6648
@VP	were assessed as at least 75 % double immunopositive for p75	6772
@VP	assessed as at least 75 % double immunopositive for p75	6777
@VP	assessed as fibronectin + ⁄ p75-negative	6906
@VP	did not exceed 25 %	6947
@VP	exceed 25 %	6955
@VP	plating media , composition of plating media and plating substrate	7010
@VP	plating media , composition of plating media	7010
@VP	plating substrate	7058
@VP	established OECs readily expand	7096
@VP	expand	7121
@VP	expand very poorly -LRB- Richter & Roskams , 2008 -RRB-	7151
@VP	derived from cranial nerves , when assessed under identical conditions in vitro	7281
@VP	assessed under identical conditions in vitro	7315
@VP	are also significantly smaller than OECs	7375
@VP	demonstrate very different morphologies , mitosis and migration capabilities	7420
@VP	would be apparent upon visual inspection	7564
@VP	be apparent upon visual inspection	7570
@VP	rule out a few contaminating Schwann cells from sensory nerves in the mucosa	7626
@VP	contaminating Schwann cells from sensory nerves in the mucosa	7641
@VP	is minimal	7722
@VP	were plated at a density of 5600 cells ⁄ cm2 into T75 flasks for transplantation	7742
@VP	plated at a density of 5600 cells ⁄ cm2 into T75 flasks for transplantation	7747
@VP	⁄ cm2 into T75 flasks for transplantation	7781
@VP	followed by washing in phosphate-buffered saline -LRB- PBS -RRB-	7933
@VP	washing in phosphate-buffered saline -LRB- PBS -RRB-	7945
@VP	⁄ µL in DMEM ⁄ F-12	8049
@VP	ranged from 11 to 14 days in vitro	8119
@VP	used OECs that were cryopreserved	8335
@VP	were cryopreserved	8350
@VP	cryopreserved	8355
@VP	were approved by the Animal Care Committee of the University of British Columbia	8514
@VP	approved by the Animal Care Committee of the University of British Columbia	8519
@VP	were used for behavioral and histological analysis	8628
@VP	used for behavioral and histological analysis	8633
@VP	was performed on the left side , exposing the fourth and fifth cervical segments	9162
@VP	performed on the left side , exposing the fourth and fifth cervical segments	9166
@VP	exposing the fourth and fifth cervical segments	9194
@VP	crushed for 20 s with custom-designed fine surgical forceps at a depth of 2 mm	9372
@VP	described previously	9469
@VP	see also Plunet et al. , 2008	9720
@VP	described previously	9822
@VP	attached to a Hamilton syringe	9987
@VP	dividing the suspension equally between these two points	10103
@VP	was injected , so that each rat received a total of 150 000 -- 180 000 cells	10194
@VP	injected , so that each rat received a total of 150 000 -- 180 000 cells	10198
@VP	received a total of 150 000	10225
@VP	injected at the same sites and at the same rate	10323
@VP	remained in the spinal cord and were not withdrawn with the syringe	10460
@VP	remained in the spinal cord	10460
@VP	were not withdrawn with the syringe	10492
@VP	withdrawn with the syringe	10501
@VP	was slowly pulled back	10558
@VP	pulled back	10569
@VP	repositioned	10593
@VP	closed with wound clips	10619
@VP	described previously	10778
@VP	were still anesthetized as above	10897
@VP	treated with BDNF	11189
@VP	-RRB-	11410
@VP	treated with vehicle	11421
@VP	received the vehicle solution alone	11442
@VP	was closed with wound clips	11585
@VP	closed with wound clips	11589
@VP	see Fig. 1 and Table 1 for the experimental design and more details	11614
@VP	encourages rats to use their forelimbs for vertical exploration	11854
@VP	to use their forelimbs for vertical exploration	11870
@VP	use their forelimbs for vertical exploration	11873
@VP	placed behind the cylinder to enable scoring of movements from all viewpoints	11932
@VP	to enable scoring of movements from all viewpoints	11959
@VP	enable scoring of movements from all viewpoints	11962
@VP	was scored frame by frame at a later time-point by a blinded rater	12024
@VP	scored frame by frame at a later time-point by a blinded rater	12028
@VP	contacting the wall of the cylinder during a full rear	12245
@VP	To reflect a more accurate use of the left forelimb	12301
@VP	reflect a more accurate use of the left forelimb	12304
@VP	reaching task The food-pellet reaching task used	12510
@VP	reaching task used	12540
@VP	used	12554
@VP	is adapted from Whishaw et al. -LRB- 1993 -RRB-	12559
@VP	adapted from Whishaw et al. -LRB- 1993 -RRB-	12562
@VP	was simplified elsewhere -LRB- Chan et al. , 2005 -RRB-	12601
@VP	simplified elsewhere -LRB- Chan et al. , 2005 -RRB-	12605
@VP	to reach through a 1-cm opening a food pellet placed in a dimple 2 cm away	12693
@VP	reach through a 1-cm opening a food pellet placed in a dimple 2 cm away	12696
@VP	opening a food pellet placed in a dimple 2 cm away	12717
@VP	placed in a dimple 2 cm away	12739
@VP	reaching -LRB- score 3 -RRB-	12865
@VP	grasping -LRB- score 5 -RRB-	12885
@VP	retrieving -LRB- score 7 -RRB- a food pellet	12908
@VP	see Chan et al. , 2005	12957
@VP	has been detailed elsewhere -LRB- Ramer et al. , 2004b -RRB-	13015
@VP	been detailed elsewhere -LRB- Ramer et al. , 2004b -RRB-	13019
@VP	detailed elsewhere -LRB- Ramer et al. , 2004b -RRB-	13024
@VP	was examined by using the plantar tester -LRB- Ugo Basile , Italy -RRB-	13100
@VP	examined by using the plantar tester -LRB- Ugo Basile , Italy -RRB-	13104
@VP	using the plantar tester -LRB- Ugo Basile , Italy -RRB-	13116
@VP	placed in a designed cage in a glass floor over a moveable infrared generator	13172
@VP	infrared source	13255
@VP	was positioned under the center of the palmar forepaw	13271
@VP	positioned under the center of the palmar forepaw	13275
@VP	was recorded for both forepaws	13369
@VP	recorded for both forepaws	13373
@VP	examined using the plantar aesthesiometer -LRB- Ugo Basile , Italy -RRB-	13443
@VP	using the plantar aesthesiometer -LRB- Ugo Basile , Italy -RRB-	13452
@VP	were placed in a raised cage with a wire mesh floor over the stimulator unit	13511
@VP	placed in a raised cage with a wire mesh floor over the stimulator unit	13516
@VP	was applied to the center of the palmar surface of the forepaw	13617
@VP	applied to the center of the palmar surface of the forepaw	13621
@VP	was increased from 1 to 50 g over 7 s.	13698
@VP	increased from 1 to 50 g over 7 s.	13702
@VP	were recorded for both forepaws	13769
@VP	recorded for both forepaws	13774
@VP	to ensure a control baseline , and for 4 weeks after injury and treatment	13907
@VP	to ensure a control baseline	13907
@VP	ensure a control baseline	13910
@VP	for 4 weeks after injury and treatment	13941
@VP	was measured before surgery	13999
@VP	measured before surgery	14003
@VP	were tested weekly for 4 weeks after injury and treatment	14044
@VP	tested weekly for 4 weeks after injury and treatment	14049
@VP	to perform the food-pellet reaching task	14117
@VP	perform the food-pellet reaching task	14120
@VP	reaching task	14144
@VP	to prevent any influences on other behavioral tests	14162
@VP	prevent any influences on other behavioral tests	14165
@VP	were fasted once a week the night preceding the testing day	14224
@VP	fasted once a week the night preceding the testing day	14229
@VP	preceding the testing day	14258
@VP	was stereotaxically injected into the red nucleus at a rate of 30 nL	14783
@VP	stereotaxically injected into the red nucleus at a rate of 30 nL	14787
@VP	glued to a Hamilton syringe	14910
@VP	to ensure that BDA was not withdrawn with the syringe	15104
@VP	ensure that BDA was not withdrawn with the syringe	15107
@VP	was not withdrawn with the syringe	15123
@VP	withdrawn with the syringe	15131
@VP	dissected	15489
@VP	postfixed in 4 % paraformaldehyde overnight	15500
@VP	cryoprotected in 24 % sucrose in 0.1 m phosphate buffer over 2 -- 3 days	15544
@VP	frozen in isopentane over dry ice	15618
@VP	were cut into 20-µm sections on a cryostat and stored at -RRB- 80 °C	15666
@VP	cut into 20-µm sections on a cryostat and stored at -RRB- 80 °C	15671
@VP	and stored at	15709
@VP	stored at	15713
@VP	were cut into 20-µm sections in the coronal plane	15758
@VP	cut into 20-µm sections in the coronal plane	15763
@VP	were cut into 20-µm longitudinal sections in the horizontal plane	15841
@VP	cut into 20-µm longitudinal sections in the horizontal plane	15846
@VP	cutting	15914
@VP	thawed on a slide warmer for 30 min	15944
@VP	rehydrated in 10 mm PBS three times for 5 min	15981
@VP	to prevent nonspecific binding	16105
@VP	prevent nonspecific binding	16108
@VP	were applied for 24 h at room temperature	16775
@VP	applied for 24 h at room temperature	16780
@VP	raised in donkey	16858
@VP	conjugated to Alexa 350 , Alexa 488 and Cy3	16876
@VP	were applied for 2	16924
@VP	applied for 2	16929
@VP	applied for 2	17052
@VP	were coverslipped in glycerol mounting liquid -LRB- Sigma -RRB-	17100
@VP	coverslipped in glycerol mounting liquid -LRB- Sigma -RRB-	17105
@VP	measuring the number of BDA-traced axons in three cross-sections at C2	17653
@VP	did not find any evidence for axonal regeneration	17899
@VP	find any evidence for axonal regeneration	17907
@VP	represents a measure of rubrospinal axon retraction	18210
@VP	sprouting proximal to the injury	18275
@VP	tracing	18336
@VP	measured on three different cervical coronal sections at C2	18402
@VP	equally distributed between the dorsal root entry zone and the central canal	18609
@VP	calculating the total pixels in this area	18691
@VP	circumscribing the lesion site on these former three longitudinal sections	18823
@VP	were adapted from Ramer et al. -LRB- 2004b -RRB-	19046
@VP	adapted from Ramer et al. -LRB- 2004b -RRB-	19051
@VP	equally distributed between the dorsal root entry zone and the central canal	19174
@VP	enhances the edges of the immunoreactive axonal and cellular profiles	19296
@VP	compensates for fluctuations in the brightness of the immunofluorescent signal	19377
@VP	using the same throughout the experiment	19483
@VP	was applied	19525
@VP	applied	19529
@VP	generated	19552
@VP	selected preferentially the axonal profiles	19569
@VP	to generate axonal density values -LRB- ratios -RRB-	19747
@VP	generate axonal density values -LRB- ratios -RRB-	19750
@VP	strictly speaking the density of their cytoplasmic and nuclear borders	19899
@VP	processed and plotted as a function of the distance from the lesion epicenter	20079
@VP	to detect differences in the axonal or cellular density at each given distance	20419
@VP	detect differences in the axonal or cellular density at each given distance	20422
@VP	to detect differences in behavioral outcome measurements at each time-point	20502
@VP	detect differences in behavioral outcome measurements at each time-point	20505
@VP	was used to detect differences between	20595
@VP	used to detect differences between	20599
@VP	to detect differences between	20604
@VP	detect differences between	20607
@VP	were further analysed using the post hoc Tukey -- Kramer test	20769
@VP	analysed using the post hoc Tukey	20782
@VP	using the post hoc Tukey	20791
@VP	did not fit a normal distribution	20862
@VP	fit a normal distribution	20870
@VP	ranked sum test was used , followed by a chi-square test	20932
@VP	was used , followed by a chi-square test	20948
@VP	used , followed by a chi-square test	20952
@VP	was taken as P < 0.05	21016
@VP	taken as P < 0.05	21020
@VP	used for histological and behavioral quantifications Fig. 1	21075
@VP	was axotomized at C4 -- C5	21217
@VP	axotomized at C4 -- C5	21221
@VP	expressing GFP were injected rostrally	21333
@VP	were injected rostrally	21348
@VP	injected rostrally	21353
@VP	caudally -LRB- 1 mm -RRB- to the lesion epicenter	21376
@VP	was injected as control into the same locations	21422
@VP	injected as control into the same locations	21426
@VP	inserted into the vicinity of the red nucleus	21640
@VP	bridge the injured spinal cord	21731
@VP	do not regenerate	21785
@VP	regenerate	21792
@VP	Note rubrospinal axons run along the white matter	21978
@VP	run along the white matter	22001
@VP	grow into the rostral OECs graft -LRB- light gray area -RRB-	22032
@VP	stop at the edge of the OEC	22088
@VP	bridging the lesion site	22128
@VP	branching within the gray matter -LRB- dark gray area -RRB-	22166
@VP	is not represented	22216
@VP	represented	22223
@VP	-LSB- biotinylated dextran amine -LRB- BDA -RRB- in red -RSB-	22458
@VP	promoted regeneration of rubrospinal axons	22726
@VP	indicate the lesion epicenters	22801
@VP	occupied by cavity formation	23126
@VP	normalized on the contralateral non-injured side	23201
@VP	indicate SEM -LSB- Kruskal -- Wallis , P < 0.01 : * compared with Veh -- DMEM	23262
@VP	is not affected by the cell body treatment	23460
@VP	affected by the cell body treatment	23467
@VP	prevented retraction of rubrospinal axons from lesion epicenter	24009
@VP	* oneway anova , P < 0.05 ; compared with the control group Veh -- DMEM	24292
@VP	compared with the control group Veh -- DMEM	24317
@VP	did not promote regeneration	24415
@VP	promote regeneration	24423
@VP	increased the number of axons at C2	24448
@VP	prevented the retraction of rubrospinal terminals from the lesion epicenter	24488
@VP	decreased the axonal density slightly	24937
@VP	were reported between both groups -LRB- anova , P = 0.437 -RRB-	25003
@VP	reported between both groups -LRB- anova , P = 0.437 -RRB-	25008
@VP	indicate SEM	25068
@VP	sprouting of supraspinal axons and peripheral afferents into	25115
@VP	left column	25279
@VP	promoted poor or no regeneration of these fibers into the OECs graft	25574
@VP	caudal to the lesion site	25773
@VP	grew into the engrafted OECs	25971
@VP	engrafted OECs	25985
@VP	dotted light gray line	26281
@VP	indicate SEM	26345
@VP	revealed a time · distance interaction for SERT , TH and CGRP fibers	26402
@VP	compared with three other groups	26574
@VP	delayed and diminished functional recovery	26639
@VP	delayed	26639
@VP	diminished functional recovery	26651
@VP	to contact the wall for the cylinder	26755
@VP	contact the wall for the cylinder	26758
@VP	test before and after spinal cord injury and treatment	26792
@VP	reaching , grasping and retrieving a food pellet	26904
@VP	reaching task	27251
@VP	treated rats	27772
@VP	reaching task -LRB- B -RRB- and thermal thresholds in individual BDNF	27870
@VP	treated rats	27962
@VP	included in graphs	28045
@VP	implanted into the lesion site , but no regeneration beyond	28138
@VP	implanted into the lesion site	28138
@VP	no regeneration beyond	28174
@VP	reduces cavity formation , GFAP expression at the lesion boundary	28333
@VP	see Fig. 1 and Table 1 for experimental design	28737
@VP	fill the lesion	28791
@VP	results in the formation of a lesion	28902
@VP	is surrounded by a margin of hypertrophic , GFAP-positive astrocytes	28960
@VP	surrounded by a margin of hypertrophic , GFAP-positive astrocytes	28963
@VP	became filled with transplanted cells	29131
@VP	filled with transplanted cells	29138
@VP	invading from the roots and meninges	29186
@VP	failed to reach significance -LRB- P = 0.14 BDNF -- OEC group ; Fig 3A -RRB-	29395
@VP	to reach significance -LRB- P = 0.14 BDNF -- OEC group ; Fig 3A -RRB-	29402
@VP	reach significance -LRB- P = 0.14 BDNF -- OEC group ; Fig 3A -RRB-	29405
@VP	receiving OECs -LRB- Vehicle -- OEC and BDNF -- OEC ; Fig. 2B and C -RRB-	29751
@VP	combined with DMEM at the spinal cord	29977
@VP	resulted in a trend towards smaller cavity areas and GFAP immunoreactivity	30015
@VP	reach significance when compared with the control group -LRB- Fig. 3B -- D -RRB-	30127
@VP	compared with the control group -LRB- Fig. 3B -- D -RRB-	30151
@VP	inferred by lesion area measurement	30395
@VP	elicited by the combination of OECs with BDNF	30432
@VP	was not different from OEC or BDNF treatment	30478
@VP	were not additive	30547
@VP	examined the regeneration of rubrospinal axons by labeling them	30933
@VP	labeling them	30983
@VP	transported tracer BDA	31020
@VP	retract after axotomy -LRB- Ye & Houle , 1997 ; Jin et al. , 2002 -RRB-	31072
@VP	involving rostral ⁄ caudal DMEM injections	31181
@VP	ended about 1700 µm -LRB- ± 323 µm -RRB- rostral to the lesion center	31248
@VP	to about 500 µm rostrally	31459
@VP	about 500 µm rostrally	31462
@VP	can not always distinguish atrophic retracting axons from newly sprouting axons	31539
@VP	distinguish atrophic retracting axons from newly sprouting axons	31554
@VP	sprouting axons	31603
@VP	anterogradely traced axons	31654
@VP	ended within the host tissue	31681
@VP	were only rarely seen in the proximity of transplanted cells	31714
@VP	rarely seen in the proximity of transplanted cells	31724
@VP	favors the interpretation that these had retracted	31819
@VP	had retracted	31856
@VP	retracted	31860
@VP	to note	31881
@VP	note	31884
@VP	were not due to differences in the efficacy of anterograde tracing	31964
@VP	tracing	32023
@VP	filled with BDA counted on coronal -LRB- i.e. cross -	32064
@VP	counted on coronal -LRB- i.e. cross -	32080
@VP	taken at C2	32122
@VP	was lower in the control group	32134
@VP	examined the sprouting of identified supra-spinal axons and peripheral afferents	32874
@VP	grew into the engrafted OECs	33239
@VP	engrafted OECs	33253
@VP	was higher caudal to the lesion site	33520
@VP	was not significantly different among the groups -LRB- Fig. 7G -- I -RRB-	33578
@VP	containing CGRP	33699
@VP	was highest inside the transplant with Vehicle -- OEC treatment	33923
@VP	had pronounced effects on the sprouting of SERT - , TH - and CGRPpositive axons	34169
@VP	injured	34485
@VP	reaching task	34605
@VP	is scored as ` left plus both ' together	34775
@VP	scored as ` left plus both ' together	34778
@VP	received control treatment or any of the two monotreatments	35172
@VP	treated with the combinatorial treatment of BDNF and OECs	35284
@VP	indicating that the left forelimb was hardly used at all	35343
@VP	was hardly used at all	35377
@VP	used at all	35388
@VP	were performed with the right paw	35421
@VP	performed with the right paw	35426
@VP	returned to the levels of other groups	35670
@VP	reaching task	35834
@VP	reaching task scaled on 10 points	35950
@VP	scaled on 10 points	35964
@VP	reach forward , touch , grasp	36022
@VP	reach forward	36022
@VP	see Chan et al. , 2005 for details of the scale	36100
@VP	were able to reach forward and touch the pellet	36216
@VP	to reach forward and touch the pellet	36226
@VP	reach forward and touch the pellet	36229
@VP	reach forward	36229
@VP	touch the pellet	36247
@VP	failed to grasp it -LRB- score 3 -RRB- during the first 3 weeks post-injury	36269
@VP	to grasp it -LRB- score 3 -RRB- during the first 3 weeks post-injury	36276
@VP	grasp it -LRB- score 3 -RRB- during the first 3 weeks post-injury	36279
@VP	improved	36352
@VP	grasp -LRB- score 5 -RRB-	36378
@VP	retrieve -LRB- score 7 -RRB-	36413
@VP	to lift their left injured forelimb	36584
@VP	lift their left injured forelimb	36587
@VP	reach forward -LRB- average score of 2 -RRB- during the 4 weeks of observation	36631
@VP	recovered	36847
@VP	observed in the cylinder and reaching tests	37031
@VP	observed in the cylinder	37031
@VP	reaching tests	37060
@VP	were aggravated by the combination of OEC transplants and BDNF	37075
@VP	aggravated by the combination of OEC transplants and BDNF	37080
@VP	tested whether this might be due to a sensory alteration in the forepaws	37242
@VP	might be due to a sensory alteration in the forepaws	37262
@VP	be due to a sensory alteration in the forepaws	37268
@VP	Plotting the motor scores against the sensory thresholds	37951
@VP	observed in BDNF	38210
@VP	appeared to correlate with an alteration in mechanical and thermal sensations	38236
@VP	to correlate with an alteration in mechanical and thermal sensations	38245
@VP	correlate with an alteration in mechanical and thermal sensations	38248
@VP	using BDNF alone	38846
@VP	tended to reduce the lesion size of the spinal cord	38889
@VP	to reduce the lesion size of the spinal cord	38896
@VP	reduce the lesion size of the spinal cord	38899
@VP	reduced cavitation and astrocytic hypertrophy	38972
@VP	increased the number of rubrospinal axons rostral to the lesion site , however	39066
@VP	correlated with hypersensitivity of the forepaw	39434
@VP	transplanting neonatal LP-OECs	39514
@VP	reduced lesion volumes	39819
@VP	indicating no apparent additive effects	40114
@VP	sprouting than in the control group	40315
@VP	is not possible to distinguish these two scenarios in our experiments	40355
@VP	to distinguish these two scenarios in our experiments	40371
@VP	distinguish these two scenarios in our experiments	40374
@VP	were not additive	40664
@VP	was equally good with BDNF or OEC application alone	40716
@VP	filled the lesion site	40932
@VP	might have migrated between the axonal stumps of the rubrospinal tract	41007
@VP	have migrated between the axonal stumps of the rubrospinal tract	41013
@VP	migrated between the axonal stumps of the rubrospinal tract	41018
@VP	might have sprouted between the transplanted cells	41111
@VP	have sprouted between the transplanted cells	41117
@VP	sprouted between the transplanted cells	41122
@VP	was no evidence for rubrospinal regeneration into or beyond the injury site	41169
@VP	were transduced to express trophic factors -LRB- Ruitenberg et al. , 2003 -RRB-	41421
@VP	transduced to express trophic factors -LRB- Ruitenberg et al. , 2003 -RRB-	41426
@VP	to express trophic factors -LRB- Ruitenberg et al. , 2003 -RRB-	41437
@VP	express trophic factors -LRB- Ruitenberg et al. , 2003 -RRB-	41440
@VP	failed to stimulate rubrospinal axon growth into the transplants	42009
@VP	to stimulate rubrospinal axon growth into the transplants	42016
@VP	stimulate rubrospinal axon growth into the transplants	42019
@VP	overexpressed by transplanted cells -LRB- Ruitenberg et al. , 2003 -RRB-	42159
@VP	applied to the cell bodies	42238
@VP	possibly released by the growing rubrospinal axons	42269
@VP	increased BDNF mRNA in these neurons -LRB- Kobayashi et al. , 1997 -RRB-	42354
@VP	may create a gradient	42463
@VP	create a gradient	42467
@VP	may act as a neurotropic attractant in the lesion center	42494
@VP	act as a neurotropic attractant in the lesion center	42498
@VP	would be the axons of the proximal tract themselves	42592
@VP	be the axons of the proximal tract themselves	42598
@VP	reversed	42658
@VP	sprouting into the OEC-filled lesion	42959
@VP	was apparent with this treatment in the present study	43002
@VP	could have played some role	43156
@VP	have played some role	43162
@VP	played some role	43167
@VP	might have resulted in more regeneration	43213
@VP	have resulted in more regeneration	43219
@VP	resulted in more regeneration	43224
@VP	were	43577
@VP	encountered in a nerve	43685
@VP	aligned by long basal lamina tubes	43743
@VP	may stimulate an adverse immune response	43813
@VP	stimulate an adverse immune response	43817
@VP	cultured for up to 40 passages	44163
@VP	produced an immortalized line -LRB- now commercialized by RhinoCytes -RRB-	44254
@VP	immortalized line -LRB- now commercialized by RhinoCytes -RRB-	44266
@VP	now commercialized by RhinoCytes	44285
@VP	claimed by these authors	44524
@VP	to find functional recovery ⁄ compensation in a cylinder	44560
@VP	find functional recovery ⁄ compensation in a cylinder	44563
@VP	might be due to intrinsic differences between cell types -LRB- LP vs.	44885
@VP	be due to intrinsic differences between cell types -LRB- LP vs.	44891
@VP	applied	45112
@VP	and delayed functional recovery	45223
@VP	delayed functional recovery	45227
@VP	observe lowered thresholds after BDNF infusion alone -LRB- BDNF -- DMEM -RRB-	45831
@VP	observed in our combined OEC	45936
@VP	were due to an unexpected combinatorial effect	45976
@VP	can only speculate on the possible mechanism	46027
@VP	speculate on the possible mechanism	46036
@VP	may be the case for LP-OECs	46482
@VP	be the case for LP-OECs	46486
@VP	increasing spinal BDNF delivery via axonal transport to their terminals	46676
@VP	is conflicting	46773
@VP	have had an effect on sensory thresholds in the absence of cell transplantation	47373
@VP	had an effect on sensory thresholds in the absence of cell transplantation	47378
@VP	involving the medulla	47471
@VP	enhanced the sensitization effect of dorsal horn neurons by OECs transplants	47504
@VP	bridged the injured spinal cord and reduced astrocyte hypertrophy	47649
@VP	bridged the injured spinal cord	47649
@VP	reduced astrocyte hypertrophy	47685
@VP	to promote regeneration of rubrospinal axons through and beyond the lesion site	47728
@VP	promote regeneration of rubrospinal axons through and beyond the lesion site	47731
@VP	diminished	47900
@VP	correlated with lowered sensory thresholds in the forepaw	47954
@VP	enhance axonal growth -LRB- Kobayashi et al. , 1997 ; Kwon et al. , 2002 -RRB-	48334
@VP	may delay fine motor recovery	48467
@VP	delay fine motor recovery	48471
@VP	needed that are not likely to elicit adverse effects especially in combinations	48585
@VP	are not likely to elicit adverse effects especially in combinations	48597
@VP	to elicit adverse effects especially in combinations	48612
@VP	elicit adverse effects especially in combinations	48615
@VP	may have demonstrated some benefits alone	48854
@VP	have demonstrated some benefits alone	48858
@VP	demonstrated some benefits alone	48863
@VP	biotinylated dextran amine	49312
